<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Calcium channel blockers versus other classes of drugs for hypertension - Zhu, J - 2022 | Cochrane Library</title> <meta content="Calcium channel blockers versus other classes of drugs for hypertension - Zhu, J - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003654.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Calcium channel blockers versus other classes of drugs for hypertension - Zhu, J - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003654.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003654.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Calcium channel blockers versus other classes of drugs for hypertension" name="citation_title"/> <meta content="Jiaying Zhu" name="citation_author"/> <meta content="Ning Chen" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Muke Zhou" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Jian Guo" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Cairong Zhu" name="citation_author"/> <meta content="School of Public Health, Sichuan University" name="citation_author_institution"/> <meta content="Jie Zhou" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Mengmeng Ma" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Li He" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="heli2003new@126.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD003654.pub6" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/01/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003654.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003654.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003654.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Angiotensin-Converting Enzyme Inhibitors [therapeutic use]; Antihypertensive Agents [adverse effects]; Calcium Channel Blockers [adverse effects]; *Hypertension [drug therapy]; *Pharmaceutical Preparations" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003654.pub6&amp;doi=10.1002/14651858.CD003654.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="p32VIvbS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003654\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003654\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","pt","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003654.pub6",title:"Calcium channel blockers versus other classes of drugs for hypertension",firstPublishedDate:"Jan 9, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hypertension Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003654.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003654.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003654.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003654.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003654.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003654.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003654.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003654.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003654.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003654.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13356 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003654.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-sec-0064"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-sec-0058"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/appendices#CD003654-sec-0069"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/table_n/CD003654StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/table_n/CD003654StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Calcium channel blockers versus other classes of drugs for hypertension</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information#CD003654-cr-0004">Jiaying Zhu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information#CD003654-cr-0005">Ning Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information#CD003654-cr-0006">Muke Zhou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information#CD003654-cr-0007">Jian Guo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information#CD003654-cr-0008">Cairong Zhu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information#CD003654-cr-0009">Jie Zhou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information#CD003654-cr-0010">Mengmeng Ma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information#CD003654-cr-0011"><i class="icon corresponding-author fa fa-envelope"></i>Li He</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information/en#CD003654-sec-0075">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 January 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003654.pub6">https://doi.org/10.1002/14651858.CD003654.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003654-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003654-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003654-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003654-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003654-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD003654-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003654-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003654-abs-0001" lang="en"> <section id="CD003654-sec-0001"> <h3 class="title" id="CD003654-sec-0001">Background</h3> <p>This is the first update of a review published in 2010. While calcium channel blockers (CCBs) are often recommended as a first‐line drug to treat hypertension, the effect of CCBs on the prevention of cardiovascular events, as compared with other antihypertensive drug classes, is still debated. </p> </section> <section id="CD003654-sec-0002"> <h3 class="title" id="CD003654-sec-0002">Objectives</h3> <p>To determine whether CCBs used as first‐line therapy for hypertension are different from other classes of antihypertensive drugs in reducing the incidence of major adverse cardiovascular events. </p> </section> <section id="CD003654-sec-0003"> <h3 class="title" id="CD003654-sec-0003">Search methods</h3> <p>For this updated review, the Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials (RCTs) up to 1 September 2020: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL 2020, Issue 1), Ovid MEDLINE, Ovid Embase, the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov. We also contacted the authors of relevant papers regarding further published and unpublished work and checked the references of published studies to identify additional trials. The searches had no language restrictions. </p> </section> <section id="CD003654-sec-0004"> <h3 class="title" id="CD003654-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing first‐line CCBs with other antihypertensive classes, with at least 100 randomised hypertensive participants and a follow‐up of at least two years. </p> </section> <section id="CD003654-sec-0005"> <h3 class="title" id="CD003654-sec-0005">Data collection and analysis</h3> <p>Three review authors independently selected the included trials, evaluated the risk of bias, and entered the data for analysis. Any disagreements were resolved through discussion. We contacted study authors for additional information. </p> </section> <section id="CD003654-sec-0006"> <h3 class="title" id="CD003654-sec-0006">Main results</h3> <p>This update contains five new trials. We included a total of 23 RCTs (18 dihydropyridines, 4 non‐dihydropyridines, 1 not specified) with 153,849 participants with hypertension. All‐cause mortality was not different between first‐line CCBs and any other antihypertensive classes. As compared to diuretics, CCBs probably increased  major cardiovascular events (risk ratio (RR) 1.05, 95% confidence interval (CI) 1.00 to 1.09, P = 0.03) and increased congestive heart failure events (RR 1.37, 95% CI 1.25 to 1.51, moderate‐certainty evidence). As compared to beta‐blockers, CCBs reduced the following outcomes: major cardiovascular events (RR 0.84, 95% CI 0.77 to 0.92), stroke (RR 0.77, 95% CI 0.67 to 0.88, moderate‐certainty evidence), and cardiovascular mortality (RR 0.90, 95% CI 0.81 to 0.99, low‐certainty evidence). As compared to angiotensin‐converting enzyme (ACE) inhibitors, CCBs reduced stroke (RR 0.90, 95% CI 0.81 to 0.99, low‐certainty evidence) and increased congestive heart failure (RR 1.16, 95% CI 1.06 to 1.28, low‐certainty evidence). As compared to angiotensin receptor blockers (ARBs), CCBs reduced myocardial infarction (RR 0.82, 95% CI 0.72 to 0.94, moderate‐certainty evidence) and increased congestive heart failure (RR 1.20, 95% CI 1.06 to 1.36, low‐certainty evidence). </p> </section> <section id="CD003654-sec-0007"> <h3 class="title" id="CD003654-sec-0007">Authors' conclusions</h3> <p>For the treatment of hypertension, there is moderate certainty evidence that diuretics reduce major cardiovascular events and congestive heart failure more than CCBs. There is low to moderate certainty evidence that CCBs probably reduce major cardiovascular events more than beta‐blockers. There is low to moderate certainty evidence that CCBs reduced stroke when compared to angiotensin‐converting enzyme (ACE) inhibitors and reduced myocardial infarction when compared to angiotensin receptor blockers (ARBs), but increased congestive heart failure when compared to ACE inhibitors and ARBs. Many of the differences found in the current review are not robust, and further trials might change the conclusions. More well‐designed RCTs studying the mortality and morbidity of individuals taking CCBs as compared with other antihypertensive drug classes are needed for patients with different stages of hypertension, different ages, and with different comorbidities such as diabetes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003654-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003654-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003654-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003654-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003654-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003654-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003654-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003654-abs-0016">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003654-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003654-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD003654-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003654-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003654-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003654-abs-0002" lang="en"> <h3>Calcium channel blockers versus other classes of drugs for hypertension</h3> <p><b>What is the aim of this review?</b> </p> <p>In this first update of a review published in 2010, we wanted to find out if calcium channel blockers (CCBs) can prevent harmful cardiovascular events such as stroke, heart attack, and heart failure when compared to other antihypertensive (blood pressure‐lowering) medications used for individuals with raised blood pressure (hypertension). </p> <p><b>Background</b> </p> <p>Appropriate lowering of elevated blood pressure in individuals with hypertension can reduce the amount of major complications of hypertension, such as stroke, heart attack, congestive heart failure, and even death. CCBs are used as a first‐line blood pressure‐lowering medication, but whether this is the best way to reduce harmful cardiovascular events has been a matter of debate. </p> <p><b>Search date</b> </p> <p>We collected and analysed all relevant studies up to 01 September 2020.</p> <p><b>Study characteristics</b> </p> <p>We found 23 relevant studies conducted in Europe, North America, Oceania, Israel, and Japan. The studies compared treatment with CCBs versus treatment with other classes of blood pressure‐lowering medications in people with hypertension and included 153,849 participants. Follow‐up of trial participants ranged from 2 to 5.3 years. </p> <p><b>Key results</b> </p> <p>There was no difference in deaths from all causes between CCBs and other blood pressure‐lowering medications. Diuretics probably reduce total cardiovascular events and congestive heart failure more than CCBs. CCBs probably reduce total cardiovascular events more than beta‐blockers. CCBs reduced stroke when compared to angiotensin‐converting enzyme (ACE) inhibitors and reduced heart attack when compared to angiotensin receptor blockers (ARBs), but increased congestive heart failure when compared to ACE inhibitors and ARBs. </p> <p><b>Quality of the evidence</b> </p> <p>We assessed the quality of the evidence as mostly moderate, although more trials are desirable. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003654-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003654-sec-0064"></div> <h3 class="title" id="CD003654-sec-0065">Implications for practice</h3> <section id="CD003654-sec-0065"> <p>This update changed some conclusions of the previous version of this review. First‐line calcium channel blockers (CCBs) do not affect total mortality as compared to other antihypertensive drug classes. First‐line CCBs reduce major cardiovascular events, stroke, and cardiovascular mortality as compared to beta‐blockers. First‐line CCBs increase major cardiovascular and congestive heart failure events as compared to diuretics. First‐line CCBs reduce stroke as compared to angiotensin‐converting enzyme (ACE) inhibitors and myocardial infarction as compared to angiotensin receptor blockers (ARBs), but they increase congestive heart failure events as compared to both ACE inhibitors and ARBs. </p> <p>The review shows an advantage of diuretics over CCBs in reducing major cardiovascular mortality and congestive heart failure events. We found evidence supporting CCBs over beta‐blockers in reduce major cardiovascular events, stroke, and cardiovascular mortality. It should be noted that many of the differences found in the current review are not robust, and further trials might change the conclusions. It will therefore be important to follow the research in this field closely and update this review when new data become available. </p> </section> <h3 class="title" id="CD003654-sec-0066">Implications for research</h3> <section id="CD003654-sec-0066"> <p>More well‐designed randomised controlled trials comparing CCBs with other types of antihypertensive drugs and combinations of CCBs with other antihypertensive drug classes are needed, especially for individuals with comorbidities such as diabetes, coronary heart disease, and nephropathy. These trials must avoid confounding factors to the greatest degree possible, such as by ensuring that the secondary drugs added to each arm of the trial are the same. It is important that all relevant outcomes are well defined and reported. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003654-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003654-sec-0008"></div> <div class="table" id="CD003654-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">CCBs versus diuretic for hypertension</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CCBs versus diuretic for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with hypertension<br/><b>Settings:</b> outpatients or inpatients<br/><b>Intervention:</b> CCBs versus diuretic<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CCBs versus diuretic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 2 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98 </b><br/>(0.92 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35,057<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNH 83 (95%CI 53 to 187)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b><br/>(111 to 126) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00 </b><br/>(0.92 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,072<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 146 (95%CI 81 to 729)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b><br/>(68 to 79) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94 </b><br/>(0.84 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,072<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 236 (95%CI 120 to 5816)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b><br/>(33 to 42) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Congestive heart failure</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.37 </b><br/>(1.25 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,072<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNH 107 (95% CI 71 to 213)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b><br/>(56 to 68) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular mortality</b><br/>Follow‐up: 2 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02 </b><br/>(0.93 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32,721<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 242 (95% CI 111 to 1377)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(50 to 60) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>  </p> <p><b>CCB:</b> calcium channel blocker; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>NNH:</b> number needed to harm; <b>NNT:</b> number needed to treat </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate.<br/>  </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>All studies were blinded, but two of them did not describe the method of blinding. All studies mentioned randomisation, but only three studies provided details; only one study described allocation concealment.<br/><sup>2</sup>All studies were blinded, but one of them did not describe the method of blinding. All studies mentioned randomisation, but two of them did not provide details; only one study described allocation concealment.<br/><sup>3</sup>All four studies were blinded, but one of them did not describe the method of blinding. All studies mentioned randomisation, but two of them did not provide details; only one study described allocation concealment. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003654-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CCBs versus β‐blocker for hypertension</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CCBs versus β‐blocker for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with hypertension<br/><b>Settings:</b> outpatients or inpatients<br/><b>Intervention:</b> CCBs versus β‐blocker </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CCBs versus β‐blocker</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 2.7 to 5.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94</b> <br/>(0.88 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44,825<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 194 (95%CI 99 to 4004)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b><br/>(70 to 79) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.90</b> <br/>(0.79 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22,249<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 223 (95%CI 102 to 1190)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b><br/>(36 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.77</b> <br/>(0.67 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22,249<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 104 (95%CI 69 to 210)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b><br/>(27 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Congestive heart failure</b><br/>Follow‐up: 4 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b> <br/>(0.67 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19,915<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 279 (95%CI 141 to 12238)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><br/>(12 to 19) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular mortality</b><br/>Follow‐up: 2.7 to 5.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.90</b> <br/>(0.81 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44,825<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 279 (95%CI 145 to 3783)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b><br/>(29 to 35) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CCB:</b> calcium channel blocker; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>NNT:</b> number needed to treat </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Only two studies described allocation concealment.<br/><sup>2</sup>Two studies did not describe allocation concealment.<br/><sup>3</sup>Wide 95% CI crossing the line of no effect and low event rate.<br/><sup>4</sup>I<sup>2</sup> &gt; 60%. Effect size varied considerably. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003654-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CCBs versus ACE inhibitor for hypertension</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CCBs versus ACE inhibitor for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with hypertension<br/><b>Settings:</b> outpatients or inpatients<br/><b>Intervention:</b> CCBs versus ACE inhibitor </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CCBs versus ACE inhibitor</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97</b> <br/>(0.91 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27,999<br/>(7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 282 (95%CI 89 to 240)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>122 per 1000</b><br/>(115 to 130) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction</b><br/>Follow‐up: 3 to 5.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b> <br/>(0.97 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27,999<br/>(7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 235 (95%CI 96 to 541)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b><br/>(69 to 81) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/>Follow‐up: 3 to 5.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.90</b> <br/>(0.81 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27,999<br/>(7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 185 (95%CI 95 to 2863)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b><br/>(42 to 51) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Congestive heart failure</b><br/>Follow‐up: median 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b> <br/>(1.06 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25,276<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 94 (95%CI 59 to 222)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b><br/>(66 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular mortality</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98</b> <br/>(0.89 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27,619<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 923 (95%CI 148 to 219)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b><br/>(55 to 66) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ACE:</b> angiotensin‐converting enzyme; <b>CCB:</b> calcium channel blocker; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>NNT:</b> number needed to treat </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>In one study, study drugs were administered open‐label. All studies mentioned randomisation, but two of them did not provide details; only three studies described allocation concealment.<br/><sup>2</sup>In one study, when BP was not well‐controlled on monotherapy, the other study drug was added.<br/><sup>3</sup>I<sup>2</sup> &gt; 60%; direction and size of effect inconsistent.<br/><sup>4</sup>All studies mentioned randomisation, but two of them did not provide details; only two studies described allocation concealment.<br/><sup>5</sup>Wide 95% CI crossing the line of no effect and low event rate.<br/><sup>6</sup>All studies mentioned randomisation, but two of them did not provide details; only three studies described allocation concealment. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003654-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">CCBs versus ARB for hypertension</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CCBs versus ARB for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with hypertension<br/><b>Settings:</b> outpatients or inpatients<br/><b>Intervention:</b> CCBs versus ARB </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>comments</b> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CCBs versus ARB</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 2 to 5.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> <br/>(0.92 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25,611<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 3128 (95%CI 143 to 157)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b><br/>(75 to 88) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction</b><br/>Follow‐up: 2 to 5.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.82</b> <br/>(0.72 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25,611<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 157 (95%CI 93 to 492)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b><br/>(26 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/>Follow‐up: 2.6 to 5.5 </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.89</b> <br/>(0.76 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25,611<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 226 (95%CI 115 to 8570)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b><br/>(26 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Congestive heart failure</b><br/>Follow‐up: mean 2.6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.20</b> <br/>(1.06 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23,265<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 94 (95%CI 59 to 222)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b><br/>(40 to 51) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular mortality</b><br/>Follow‐up: mean 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.79</b> <br/>(0.54 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4642<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 184 (95% CI 72 to 331)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><br/>(13 to 29) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ARB:</b> angiotensin receptor blocker; <b>CCB:</b> calcium channel blocker; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>NNT:</b> number needed to treat </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Only two studies described allocation concealment, and one study had withdrawals.<br/><sup>2</sup>Only three studies described allocation concealment, and one study had withdrawals.<br/><sup>3</sup>I<sup>2</sup> &gt; 60%; direction and size of effect inconsistent.<br/><sup>4</sup>One study of three did not describe allocation concealment, and one study had withdrawals. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003654-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003654-sec-0009"></div> <section id="CD003654-sec-0010"> <h3 class="title" id="CD003654-sec-0010">Description of the condition</h3> <p>Hypertension is a leading cause of death worldwide, and its prevalence has increased dramatically over the past two decades (<a href="./references#CD003654-bbs2-0074" title="GBD 2013 Risk Factors Collaborators, ForouzanfarMH , AlexanderL , AndersonHR , BachmanVF , BiryukovS , et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet2015;386:2287-323.">GBD 2015</a>). In the population‐based ARIC (Atherosclerosis Risk in Communities) study, hypertension was associated with an increased risk of coronary heart disease, stroke, heart failure, and end‐stage renal disease; 25% of all cardiovascular events were attributable to hypertension (<a href="./references#CD003654-bbs2-0070" title="ChengS , ClaggettB , CorreiaAW , ShahAM , GuptaDK , SkaliH , et al. Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study. Circulation2014;130:820-8.">Cheng 2014</a>).  </p> </section> <section id="CD003654-sec-0011"> <h3 class="title" id="CD003654-sec-0011">Description of the intervention</h3> <p>Antihypertensive therapies have established benefits in reducing the risk for major cardiovascular events. Pharmacotherapy for high blood pressure includes first‐line agents, such as diuretics, angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs), and non‐first‐line agents, such as beta‐blockers and alpha‐blockers (<a href="./references#CD003654-bbs2-0096" title="WheltonPK , CareyRM , AronowWS , Casey DE Jr, CollinsKJ , Dennison HimmelfarbC , et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension2018;71(6):1269-324.">Whelton 2018</a>).  </p> </section> <section id="CD003654-sec-0012"> <h3 class="title" id="CD003654-sec-0012">How the intervention might work</h3> <p>Different classes of antihypertensive drugs have different mechanisms of action. Previous meta‐analysis  demonstrated that all major antihypertensive drug classes (diuretics, ACE inhibitors, ARBs, beta‐blockers, and CCBs) caused a similar reduction in coronary heart disease events and stroke for a given reduction in blood pressure (<a href="./references#CD003654-bbs2-0082" title="LawMR , MorrisJK , WaldNJ . Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ2009;338:b1665.">Law 2009</a>). The systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults indicated that thiazides were associated with a lower risk of many cardiovascular outcomes compared with other antihypertensive drug classes (<a href="./references#CD003654-bbs2-0087" title="ReboussinDM , AllenNB , GriswoldME , GuallarE , HongY , LacklandDT , et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2017 Nov 13 [Epub ahead of print]. [DOI: 10.1161/HYP.0000000000000067]">Reboussin 2017</a>). CCBs significantly increased the risk of congestive heart failure as compared to diuretics, ACE inhibitors, and ARBs in a review by Thomopoulos(<a href="./references#CD003654-bbs2-0092" title="ThomopoulosC , ParatiG , ZanchettiA . Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses. Journal of Hypertension2015;33(2):195-211.">Thomopoulos 2015</a>). One previous review concluded that beta‐blockers reduced total cardiovascular events significantly less than CCBs (<a href="./references#CD003654-bbs2-0098" title="WiysongeCS , BradleyHA , VolminkJ , MayosiBM , OpieLH . Beta-blockers for hypertension. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD002003. [DOI: 10.1002/14651858.CD002003.pub2]">Wiysonge 2007</a>).  </p> </section> <section id="CD003654-sec-0013"> <h3 class="title" id="CD003654-sec-0013">Why it is important to do this review</h3> <p>The issue of first‐line drug selection is highly relevant for millions of subjects receiving drug therapy for hypertension. The benefits  in reducing the risk for major cardiovascular events of any one class of antihypertensive therapies relative to other classes has been a matter of debate. Our first systematic review compared CCBs with other classes of antihypertensive drugs in 2010 (<a href="./references#CD003654-bbs2-0102" title="ChenN , ZhouM , YangM , GuoJ , ZhuC , YangJ , et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database of Systematic Reviews2010, Issue 8. Art. No: CD003654. [DOI: 10.1002/14651858.CD003654.pub4]">Chen 2010</a>), but since then some head‐to‐head trials of CCBs versus other classes of antihypertensive drugs have been performed. These additional newer trials not included in previous systematic reviews may provide an improved understanding of the relative benefits of each class of antihypertensive therapies. This review update aims to sent the outcome data in a way that best assists clinicians in the choice of a antihypertensive drug. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003654-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003654-sec-0014"></div> <p>To determine whether CCBs used as first‐line therapy for hypertension are different from other classes of antihypertensive drugs in reducing the incidence of major adverse cardiovascular events. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003654-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003654-sec-0015"></div> <section id="CD003654-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003654-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) that randomised 100 or more participants and followed participants for at least two years. </p> </section> <section id="CD003654-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included participants with a baseline blood pressure (BP) of at least 140 mmHg systolic or 90 mmHg diastolic, measured in a standard way on at least two occasions, or participants with diabetes mellitus with a BP of more than 135/85 mmHg. If a trial was not limited to participants with elevated BP, it must have reported outcome data separately for participants with elevated BP as defined above. </p> </section> <section id="CD003654-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing first‐line CCBs with other first‐line antihypertensive classes. The majority (&gt; 70%) of participants in all study groups must be taking the assigned drug class after one year. Supplemental drugs from drug classes other than CCBs were allowed as stepped therapy. </p> </section> <section id="CD003654-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>The main outcomes of the review were as follows.</p> <section id="CD003654-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD003654-list-0001"> <li> <p>All‐cause mortality</p> </li> <li> <p>Myocardial infarction (non‐fatal and fatal MI plus sudden or rapid death)</p> </li> <li> <p>Stroke (non‐fatal and fatal stroke)</p> </li> <li> <p>Congestive heart failure</p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Major cardiovascular events (MI, congestive heart failure, stroke, and cardiovascular mortality) </p> </li> </ol> </p> </section> <section id="CD003654-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD003654-list-0002"> <li> <p>Reduction in systolic and diastolic blood pressure</p> </li> </ol> </p> </section> </section> </section> <section id="CD003654-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003654-sec-0024"> <h4 class="title">Electronic searches</h4> <p>For this update, the Cochrane Hypertension Information Specialist searched the following databases without language or publication status restrictions: </p> <p> <ul id="CD003654-list-0003"> <li> <p>the Cochrane Hypertension Specialised Register via the Cochrane Register of Studies (CRS‐Web) (searched 01 September 2020); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL, 2020, Issue 1) via CRS‐Web (searched 01 September 2020); </p> </li> <li> <p>MEDLINE Ovid, MEDLINE Ovid Epub Ahead of Print, and MEDLINE Ovid In‐Process &amp; Other Non‐Indexed Citations (searched 01 September 2020); </p> </li> <li> <p>Embase Ovid (searched 01 September 2020);</p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (searched 01 September 2020); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.it.trialsearch" target="_blank">www.who.it.trialsearch</a>) (searched 01 September 2020). </p> </li> </ul> </p> <p>The Information Specialist modelled subject strategies for databases on the search strategy designed for MEDLINE. Where appropriate, these were combined with subject strategy adaptations of the Highly Sensitive Search Strategy designed by Cochrane for identifying randomised controlled trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1.0, Box 6.4.c.)(<a href="./references#CD003654-bbs2-0077" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). The database search strategies are shown for this update in <a href="./appendices#CD003654-sec-0070">Appendix 1</a> and from the previous (2010) review in <a href="./appendices#CD003654-sec-0071">Appendix 2</a>. </p> </section> <section id="CD003654-sec-0025"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD003654-list-0004"> <li> <p>The Cochrane Hypertension Information Specialist searched the Hypertension Specialised Register segment (which includes searches of MEDLINE, Embase, and Epistemonikos for systematic reviews) to retrieve existing reviews relevant to this systematic review, so that we could scan their reference lists for additional trials. The Specialised Register also includes searches of CAB Abstracts &amp; Global Health, CINAHL (Cumulative Index to Nursing and Allied Health Literature), ProQuest Dissertations &amp; Theses, and Web of Science for controlled trials. </p> </li> <li> <p>We checked the bibliographies of included studies and any relevant systematic reviews identified for further references to relevant trials. </p> </li> <li> <p>Where necessary, we contacted authors of key papers and abstracts to request additional information about their trials. </p> </li> </ul> </p> </section> </section> <section id="CD003654-sec-0026"> <h3 class="title" id="CD003654-sec-0026">Data collection and analysis</h3> <section id="CD003654-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (Jiaying Zhu, Ning Chen) independently examined the titles and abstracts of citations identified by the electronic searches for possible inclusion. We retrieved full‐text publications of potentially relevant studies and three review authors (Jiaying Zhu, Jie Zhou and Mengmeng Ma) then independently determined study eligibility. We resolved disagreements about study eligibility by discussion and, if necessary, a fourth review author would arbitrate. </p> </section> <section id="CD003654-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (Jiaying Zhu, Jie Zhou and Mengmeng Ma) independently extracted data using a standard form, and then cross‐checked them. Muke Zhou and Jian Guo confirmed all numeric calculations and graphic interpolations. We resolved any discrepancies by consensus. </p> </section> <section id="CD003654-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The review authors (Jiaying Zhu and Mengmeng Ma) independently used the Cochrane 'Risk of bias' tool to categorize studies as having low,unclear, or high risk of bias for sequence generation, allocation sequence concealment, loss of blinding, selective reporting,incomplete reporting of outcomes, and other potential sources of bias (<a href="./references#CD003654-bbs2-0078" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at handbook.cochrane.org.">Higgins 2011a</a>).  </p> </section> <section id="CD003654-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We based quantitative analysis of outcomes on intention‐to‐treat principles as much as possible. For dichotomous outcomes, we expressed results as the risk ratio (RR) with a 95% confidence interval (CI). For combining continuous variables (systolic blood pressure reduction, diastolic blood pressure reduction), we used the mean difference (with 95% CI). </p> </section> <section id="CD003654-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual trial. For trials having more than two arms, we only included arms relevant to this review. For trials included more than one intervention group with a single comparator arm, we included both intervention groups. </p> </section> <section id="CD003654-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study investigators in the case of missing data. We based the quantitative analyses of outcomes on intention‐to‐treat results. </p> </section> <section id="CD003654-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used Chi<sup>2</sup> and I<sup>2</sup>statistics to test for heterogeneity of treatment effect among trials. </p> <p>We assessed values of the I<sup>2</sup>statistic as follows (<a href="./references#CD003654-bbs2-0078" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at handbook.cochrane.org.">Higgins 2011a</a>): </p> <p> <ul id="CD003654-list-0005"> <li> <p>0% to 40%: heterogeneity might not be important;</p> </li> <li> <p>30% to 60%: moderate heterogeneity;</p> </li> <li> <p>50% to 90%: substantial heterogeneity;</p> </li> <li> <p>75% to 100% considerable heterogeneity.</p> </li> </ul> </p> <p>We used the fixed‐effect model when there was homogeneity and used the random‐effects model to test for statistical significance where there was heterogeneity. </p> </section> <section id="CD003654-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess reporting bias following the recommendations on testing for funnel plot asymmetry as described in the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD003654-bbs2-0078" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at handbook.cochrane.org.">Higgins 2011a</a>). </p> </section> <section id="CD003654-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We performed data synthesis and analyses using the Cochrane Review Manager software, RevMan 5.4, We describe data results in tables and forest plots. We also give full details of all studies we include and exclude. We have included a standard PRISMA flow diagram. </p> </section> <section id="CD003654-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If appropriate, we would perform subgroup analyses.</p> <p>Heterogeneity among participants could be related to: age,gender, baseline blood pressure, target blood pressure, high‐risk participants, participants with comorbid conditions.<br/>Heterogeneity in treatments could be related to: form of drugs,dosage of drugs, or duration of therapy. </p> </section> <section id="CD003654-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses to examine the effects of excluding studies with a moderate or high risk of bias, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD003654-bbs2-0077" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a><i>)</i><br/>  </p> </section> <section id="CD003654-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>In this updated review, we included 'Summary of findings' tables for comparisons that included more than one trial to present the main findings of the review, which included information about the quality of the evidence, the magnitude of effects, and the sum of the available data on the main outcomes (<a href="./references#CD003654-bbs2-0089" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and‘Summary of findings' tables. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schünemann 2011a</a>). </p> <p>We assessed the quality of a body of evidence according to five GRADE considerations (study limitations, inconsistency of effect, imprecision, indirectness, and publication bias) (<a href="./references#CD003654-bbs2-0088" title="RyanR , HillS . How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group, available at cccrg.cochrane.org/author-resources. Version 3.0. 1 December 2016 (accessed prior to 2 January 2020).">Ryan 2016</a>). We downgraded the evidence from 'high certainty by one level where one of these factors was present to a serious degree and two levels if very serious. We used the methods and recommendations described in Chapter 8 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003654-bbs2-0089" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and‘Summary of findings' tables. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schünemann 2011a</a>; <a href="./references#CD003654-bbs2-0090" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011, Available from www.cochrane-handbook.org.">Schünemann 2011b</a>). We justified all decisions to downgrade the quality of the evidence using footnotes and made comments to aid reader's understanding of the review where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003654-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003654-sec-0039"></div> <section id="CD003654-sec-0040"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD003654-sec-0082" title="">Characteristics of included studies</a>; <a href="./references#CD003654-sec-0083" title="">Characteristics of excluded studies</a>. </p> <section id="CD003654-sec-0041"> <h4 class="title">Results of the search</h4> <p>The results of the search are shown in the PRISMA diagram (<a href="#CD003654-fig-0001">Figure 1</a>), We identified 4,700 records from database searches. 4,649 records remained after removal of duplicates. After screening titles and abstracts, we obtained 65 full‐text articles. Of these articles, we excluded 42 studies based on them not meeting our inclusion criteria. </p> <div class="figure" id="CD003654-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003654-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003654-sec-0042"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD003654-sec-0082" title="">Characteristics of included studies</a> for details. </p> <p>We included 23 RCTs (<a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>; <a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>; <a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>; <a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>; <a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>; <a href="./references#CD003654-bbs2-0007" title="ZanchettiA , BondMG , HennigM , NeissA , ManciaG , Dal PalùC , et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106(19):2422-7. ">ELSA</a>; <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a>; <a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>; <a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>; <a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>; <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>; <a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>; <a href="./references#CD003654-bbs2-0014" title="BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-TerrisM , CarrAA , et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA1996;276(10):785-91. BorhaniNO , MillerST , BruggerSB , SchnaperHW , CravenTE , BondMG , et al. MIDAS: hypertension and atherosclerosis, a trial of the effect of antihypertensive drug treatment on atherosclerosis. Journal of Cardiovascular Pharmacology1992;19(Suppl 3):16-20. FurbergC , ByingtonR , BorhaniN . Design features: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. ">MIDAS</a>; <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>; <a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a>; <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>; <a href="./references#CD003654-bbs2-0018" title="MalaccoE , ManciaG , RappelliA , MenottiA , ZuccaroMS , CoppiniA , et al. Treatment of isolated systolic hypertension: The SHELL Study results. Blood Pressure2003;12:160-7. ">SHELL</a>; <a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>; <a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a>; <a href="./references#CD003654-bbs2-0021" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363(9426):2022-31. MannJ , JuliusS . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998;7(3):176-83. ">VALUE</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>; <a href="./references#CD003654-bbs2-0023" title="RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA . Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension1997;15(11):1337-44. ZanchettiA , RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA . The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16(11):1667-76. ">VHAS</a>) with a total of 153,849 participants. Five of the 23 trials were new in this update (<a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>; <a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>; <a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>; <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>). </p> <p>All the included RCTs supplied explicit inclusion and exclusion criteria. Twenty trials included only hypertensive participants, but these were defined differently, as follows: 140/90 mmHg or more (<a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a>; <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>; <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>); 150/90 mmHg or more (<a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>); more than 160/95 mmHg (<a href="./references#CD003654-bbs2-0023" title="RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA . Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension1997;15(11):1337-44. ZanchettiA , RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA . The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16(11):1667-76. ">VHAS</a>); more than 135/85 mmHg for participants with diabetes mellitus (<a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>); 140 to 179 mmHg systolic and/or 90 to 109 mmHg diastolic (<a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>); 150 to 210 mmHg systolic and 95 to 115 mmHg diastolic (<a href="./references#CD003654-bbs2-0007" title="ZanchettiA , BondMG , HennigM , NeissA , ManciaG , Dal PalùC , et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106(19):2422-7. ">ELSA</a>); systolic BP ≥ 180 mmHg and/or diastolic BP ≥ 105 mmHg (<a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>); diastolic BP of 100 mmHg or more, <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>, or of 90 to 99 mmHg (<a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a>); treated hypertension with an upper limit of 175/100 mmHg or untreated hypertension of 140 to 190 mmHg systolic or 90 to 110 mmHg diastolic (<a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>); BP ≥ 160/100 mmHg for participants with untreated hypertension or BP ≥ 140/90 mmHg for participants on antihypertensive treatment (<a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>); systolic BP ≥ 150 mmHg and diastolic BP ≥ 95 mmHg, or only systolic BP ≥ 160 mmHg (<a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>); only diastolic BP ≥ 95 mmHg, <a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>, or 90 to 115 mmHg (<a href="./references#CD003654-bbs2-0014" title="BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-TerrisM , CarrAA , et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA1996;276(10):785-91. BorhaniNO , MillerST , BruggerSB , SchnaperHW , CravenTE , BondMG , et al. MIDAS: hypertension and atherosclerosis, a trial of the effect of antihypertensive drug treatment on atherosclerosis. Journal of Cardiovascular Pharmacology1992;19(Suppl 3):16-20. FurbergC , ByingtonR , BorhaniN . Design features: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. ">MIDAS</a>); 160 to 210/220 mmHg systolic and less than 115 mmHg diastolic (<a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a>; <a href="./references#CD003654-bbs2-0021" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363(9426):2022-31. MannJ , JuliusS . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998;7(3):176-83. ">VALUE</a>); ≥ 160 mmHg systolic and ≤ 95 mmHg diastolic (<a href="./references#CD003654-bbs2-0018" title="MalaccoE , ManciaG , RappelliA , MenottiA , ZuccaroMS , CoppiniA , et al. Treatment of isolated systolic hypertension: The SHELL Study results. Blood Pressure2003;12:160-7. ">SHELL</a>); systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg in participants &lt; 70 years old, or systolic BP ≥ 160 mmHg or diastolic BP ≥ 90 mmHg in participants ≥ 70 years old (<a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>); mild‐to‐moderate hypertension (<a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>). Only one trial did not limit participants to elevated BP (diastolic BP ≥ 80 mmHg) (<a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>), but it reported outcomes on participants with elevated BP (diastolic BP ≥ 90 mmHg) separately, so data for hypertensive participants could be extracted. </p> <p>Additional inclusion criteria varied for each study, as follows: with other risk factor(s) for coronary heart disease or cardiovascular disease (<a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>; <a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>; <a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>; <a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>); with coronary heart disease (<a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>; <a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>); with cardiovascular risk factors or cardiovascular disease (<a href="./references#CD003654-bbs2-0021" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363(9426):2022-31. MannJ , JuliusS . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998;7(3):176-83. ">VALUE</a>); with type 2 diabetes mellitus (non‐insulin‐dependent diabetes mellitus), <a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>; <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a>, or type 2 diabetes mellitus and nephropathy (<a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>); with glucose intolerance (type 2 diabetes or impaired glucose tolerance) (<a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>); African‐Americans with hypertensive kidney disease (<a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>).<br/>  </p> <p>All 23 included RCTs recruited participants of both sexes, but age requirements differed amongst the trials, as follows: ≥ 30 years (<a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>); &gt; 40 years (<a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>; <a href="./references#CD003654-bbs2-0014" title="BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-TerrisM , CarrAA , et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA1996;276(10):785-91. BorhaniNO , MillerST , BruggerSB , SchnaperHW , CravenTE , BondMG , et al. MIDAS: hypertension and atherosclerosis, a trial of the effect of antihypertensive drug treatment on atherosclerosis. Journal of Cardiovascular Pharmacology1992;19(Suppl 3):16-20. FurbergC , ByingtonR , BorhaniN . Design features: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. ">MIDAS</a>); &gt; 50 years (<a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>; <a href="./references#CD003654-bbs2-0021" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363(9426):2022-31. MannJ , JuliusS . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998;7(3):176-83. ">VALUE</a>); &gt; 55 years (<a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>); &gt; 60 years (<a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a>; <a href="./references#CD003654-bbs2-0018" title="MalaccoE , ManciaG , RappelliA , MenottiA , ZuccaroMS , CoppiniA , et al. Treatment of isolated systolic hypertension: The SHELL Study results. Blood Pressure2003;12:160-7. ">SHELL</a>); 18 to 70 years (<a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>); 30 to 70 years (<a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>); 30 to 75 years (<a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>); 40 to 65 years (<a href="./references#CD003654-bbs2-0023" title="RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA . Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension1997;15(11):1337-44. ZanchettiA , RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA . The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16(11):1667-76. ">VHAS</a>); 40 to 74 years (<a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>); 40 to 79 years (<a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>); 45 to 69 years (<a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a>); 45 to 75 years (<a href="./references#CD003654-bbs2-0007" title="ZanchettiA , BondMG , HennigM , NeissA , ManciaG , Dal PalùC , et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106(19):2422-7. ">ELSA</a>); 50 to 74 years (<a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>); 55 to 80 years (<a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>); under 75 years (<a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>); 70 to 84 years (<a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>). In the <a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a> trial, differing BP levels were required for participants aged &lt; 70 years and ≥ 70 years. </p> <p>Most trials followed a goal BP in their protocols, mostly less than 140/90 mmHg (<a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>; <a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>; <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a>; <a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>; <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>; <a href="./references#CD003654-bbs2-0021" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363(9426):2022-31. MannJ , JuliusS . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998;7(3):176-83. ">VALUE</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>); or less than 150/90 mmHg (<a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>); less than 130/80 mmHg for hypertensive participants with glucose intolerance (<a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>); less than 130/85 mmHg for participants with diabetes or renal impairment (<a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>; <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>); ≤ 135/85 mmHg or a decrease ≥ 10 mmHg systolic for diabetic participants (<a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>); ≤ 160/95 mmHg (<a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>); less than 90 mmHg diastolic, <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>, or 95 mmHg (<a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a>); less than 95 mmHg with a fall of at least 5 mmHg (<a href="./references#CD003654-bbs2-0007" title="ZanchettiA , BondMG , HennigM , NeissA , ManciaG , Dal PalùC , et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106(19):2422-7. ">ELSA</a>); less than 90 mmHg with a fall of at least 10 mmHg (<a href="./references#CD003654-bbs2-0014" title="BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-TerrisM , CarrAA , et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA1996;276(10):785-91. BorhaniNO , MillerST , BruggerSB , SchnaperHW , CravenTE , BondMG , et al. MIDAS: hypertension and atherosclerosis, a trial of the effect of antihypertensive drug treatment on atherosclerosis. Journal of Cardiovascular Pharmacology1992;19(Suppl 3):16-20. FurbergC , ByingtonR , BorhaniN . Design features: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. ">MIDAS</a>); reduction more than 20 mmHg or systolic BP ≤ 160 mmHg (<a href="./references#CD003654-bbs2-0018" title="MalaccoE , ManciaG , RappelliA , MenottiA , ZuccaroMS , CoppiniA , et al. Treatment of isolated systolic hypertension: The SHELL Study results. Blood Pressure2003;12:160-7. ">SHELL</a>); ≤ 90 mmHg or ≤ 95 mmHg with a reduction of at least 10% from baseline value (<a href="./references#CD003654-bbs2-0023" title="RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA . Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension1997;15(11):1337-44. ZanchettiA , RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA . The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16(11):1667-76. ">VHAS</a>); 75 mmHg or less diastolic in the intensive‐treatment group and 80 to 89 mmHg diastolic in the moderate‐treatment group (<a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>); 102 to 107 mmHg of mean arterial pressure in the usual‐goal group and 92 mmHg or less in the lower‐goal group (<a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>); a decrease ≥ 20 mmHg of BP if systolic BP was more than 160 mmHg or diastolic BP was more than 110 mmHg (<a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a>); 60 years old, systolic BP/diastolic BP 130/85 mmHg; 60 to 69 years old, systolic BP/diastolic BP 140/90 mmHg; 70 to 79 years old, systolic BP/diastolic BP 150/90 mmHg; 80 years old, systolic BP/diastolic BP 160/90 mmHg (<a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>); usual control 125 to 134/80 to 84 mmHg and tight control &lt; 125/&lt; 80 mmHg (<a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>). </p> <p>Of CCBs for hypertension, dihydropyridines (DHPs) were the most commonly studied, especially amlodipine (<a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>; <a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>; <a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>; <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a>; <a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>; <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>; <a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a>; <a href="./references#CD003654-bbs2-0021" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363(9426):2022-31. MannJ , JuliusS . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998;7(3):176-83. ">VALUE</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>). Other DHPs studied included nifedipine (<a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>; <a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>), felodipine (<a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>), nisoldipine (<a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>), nicardipine (<a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a>), lacidipine (<a href="./references#CD003654-bbs2-0007" title="ZanchettiA , BondMG , HennigM , NeissA , ManciaG , Dal PalùC , et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106(19):2422-7. ">ELSA</a>; <a href="./references#CD003654-bbs2-0018" title="MalaccoE , ManciaG , RappelliA , MenottiA , ZuccaroMS , CoppiniA , et al. Treatment of isolated systolic hypertension: The SHELL Study results. Blood Pressure2003;12:160-7. ">SHELL</a>), and isradipine (<a href="./references#CD003654-bbs2-0014" title="BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-TerrisM , CarrAA , et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA1996;276(10):785-91. BorhaniNO , MillerST , BruggerSB , SchnaperHW , CravenTE , BondMG , et al. MIDAS: hypertension and atherosclerosis, a trial of the effect of antihypertensive drug treatment on atherosclerosis. Journal of Cardiovascular Pharmacology1992;19(Suppl 3):16-20. FurbergC , ByingtonR , BorhaniN . Design features: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. ">MIDAS</a>). Other trials evaluated non‐DHPs such as an aralkylamine derivative verapamil, <a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>; <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>; <a href="./references#CD003654-bbs2-0023" title="RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA . Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension1997;15(11):1337-44. ZanchettiA , RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA . The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16(11):1667-76. ">VHAS</a>, and a benzothiazepine derivative diltiazem (<a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>). One study did not describe the specific CCBs used (<a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>). The included RCTs compared one of the above CCBs to other classes of antihypertensive drugs, including: a diuretic (<a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>; <a href="./references#CD003654-bbs2-0014" title="BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-TerrisM , CarrAA , et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA1996;276(10):785-91. BorhaniNO , MillerST , BruggerSB , SchnaperHW , CravenTE , BondMG , et al. MIDAS: hypertension and atherosclerosis, a trial of the effect of antihypertensive drug treatment on atherosclerosis. Journal of Cardiovascular Pharmacology1992;19(Suppl 3):16-20. FurbergC , ByingtonR , BorhaniN . Design features: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. ">MIDAS</a>; <a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a>; <a href="./references#CD003654-bbs2-0018" title="MalaccoE , ManciaG , RappelliA , MenottiA , ZuccaroMS , CoppiniA , et al. Treatment of isolated systolic hypertension: The SHELL Study results. Blood Pressure2003;12:160-7. ">SHELL</a>; <a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a>; <a href="./references#CD003654-bbs2-0023" title="RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA . Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension1997;15(11):1337-44. ZanchettiA , RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA . The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16(11):1667-76. ">VHAS</a>); a beta‐blocker (<a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>; <a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>; <a href="./references#CD003654-bbs2-0007" title="ZanchettiA , BondMG , HennigM , NeissA , ManciaG , Dal PalùC , et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106(19):2422-7. ">ELSA</a>; <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>; <a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a>); a diuretic or beta‐blocker, or both, data of which could not be separated for each drug (<a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>; <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>; <a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>); an alpha‐1‐antagonist (<a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a>); an ACE inhibitor (<a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>; <a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>; <a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a>; <a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>; <a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>; <a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>; <a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a>); or an ARB (<a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>; <a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>; <a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>; <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>; <a href="./references#CD003654-bbs2-0021" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363(9426):2022-31. MannJ , JuliusS . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998;7(3):176-83. ">VALUE</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>). </p> <p>Supplemental antihypertensive agents other than the study drugs were permitted in most of the included trials, often administered sequentially to achieve BP goals (<a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>; <a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>; <a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>; <a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>; <a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>; <a href="./references#CD003654-bbs2-0007" title="ZanchettiA , BondMG , HennigM , NeissA , ManciaG , Dal PalùC , et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106(19):2422-7. ">ELSA</a>; <a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>; <a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>; <a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>; <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>; <a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>; <a href="./references#CD003654-bbs2-0014" title="BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-TerrisM , CarrAA , et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA1996;276(10):785-91. BorhaniNO , MillerST , BruggerSB , SchnaperHW , CravenTE , BondMG , et al. MIDAS: hypertension and atherosclerosis, a trial of the effect of antihypertensive drug treatment on atherosclerosis. Journal of Cardiovascular Pharmacology1992;19(Suppl 3):16-20. FurbergC , ByingtonR , BorhaniN . Design features: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. ">MIDAS</a>; <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>; <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>; <a href="./references#CD003654-bbs2-0018" title="MalaccoE , ManciaG , RappelliA , MenottiA , ZuccaroMS , CoppiniA , et al. Treatment of isolated systolic hypertension: The SHELL Study results. Blood Pressure2003;12:160-7. ">SHELL</a>; <a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>; <a href="./references#CD003654-bbs2-0021" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363(9426):2022-31. MannJ , JuliusS . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998;7(3):176-83. ">VALUE</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>; <a href="./references#CD003654-bbs2-0023" title="RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA . Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension1997;15(11):1337-44. ZanchettiA , RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA . The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16(11):1667-76. ">VHAS</a>). The <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a> trial added the study drug of the other group to participants whose BP was not controlled well. The <a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a> trial studied five classes of first‐line antihypertensive drugs, and added chlortalidone or enalapril, both of which were study drugs, to participants to control BP. <a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a> prohibited the use of any other antihypertensive drugs. </p> <p>Outcomes differed amongst studies, but results for our planned outcomes of cardiovascular events and BP changes were reported in most trials. However, fatal MI, stroke, and heart failure were sometimes contained in death events, and in some trials components of cardiovascular events were not reported separately. As a result, not every trial supplied data to each meta‐analysis for outcomes of this review. Only two trials explicitly presented the mean BP changes with standard deviations (SDs), <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>, or standard errors, <a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a>, which could be directly inputted into Review Manager 5 for analysis. In some other trials, mean BP change could be calculated by subtracting the baseline value at randomisation from the value reported at the end of the trial, but SDs for changes were not reported. We calculated change‐from‐baseline SDs when baseline and final values were known (<a href="./references#CD003654-bbs2-0079" title="HigginsJPT , DeeksJJ , AltmanDG , editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at handbook.cochrane.org.">Higgins 2011b</a>) (<a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>; <a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a>; <a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a>; <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>; <a href="./references#CD003654-bbs2-0021" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363(9426):2022-31. MannJ , JuliusS . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998;7(3):176-83. ">VALUE</a>). However, when trials did not supply SDs for the baseline and final BPs, the BP results were not entered into the meta‐analysis (<a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>; <a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>; <a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>; <a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>; <a href="./references#CD003654-bbs2-0007" title="ZanchettiA , BondMG , HennigM , NeissA , ManciaG , Dal PalùC , et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106(19):2422-7. ">ELSA</a>; <a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>; <a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>; <a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>; <a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>; <a href="./references#CD003654-bbs2-0014" title="BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-TerrisM , CarrAA , et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA1996;276(10):785-91. BorhaniNO , MillerST , BruggerSB , SchnaperHW , CravenTE , BondMG , et al. MIDAS: hypertension and atherosclerosis, a trial of the effect of antihypertensive drug treatment on atherosclerosis. Journal of Cardiovascular Pharmacology1992;19(Suppl 3):16-20. FurbergC , ByingtonR , BorhaniN . Design features: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. ">MIDAS</a>; <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>; <a href="./references#CD003654-bbs2-0018" title="MalaccoE , ManciaG , RappelliA , MenottiA , ZuccaroMS , CoppiniA , et al. Treatment of isolated systolic hypertension: The SHELL Study results. Blood Pressure2003;12:160-7. ">SHELL</a>; <a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>; <a href="./references#CD003654-bbs2-0023" title="RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA . Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension1997;15(11):1337-44. ZanchettiA , RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA . The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16(11):1667-76. ">VHAS</a>). </p> <p>Mean duration of follow‐up ranged from 2 to 5.3 years. One trial stated that no participant was lost to follow‐up and no participant refused to continue in the study (<a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>), whilst loss to follow‐up and withdrawal were reported in the other 22 trials. All trials with the exception of <a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a> stated that an intention‐to‐treat analysis was performed. </p> </section> <section id="CD003654-sec-0043"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD003654-sec-0083" title="">Characteristics of excluded studies</a> for details. </p> <p>The reasons for exclusion included: non‐randomised design (<a href="./references#CD003654-bbs2-0024" title="AbascalVM , LarsonMG , EvansJC , BlohmAT , PoliK , LevyD , et al. Calcium antagonists and mortality risk in men and women with hypertension in the Framingham Heart Study. Archives of Internal Medicine1998;158(17):1882-6. ">Abascal 1998</a>; <a href="./references#CD003654-bbs2-0030" title="BhadP , AyalasomayajulaS , KaranR , LeonS , RiviereGJ , SunkaraG , et al. Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. Journal of Clinical Pharmacology2011;51:933-42. ">Bhad 2011</a>; <a href="./references#CD003654-bbs2-0037" title="BulpittCJ , PalmerAJ , BeeversDG , ColesEC , LedinghamJG , PetrieJC , et al. Calcium channel blockers and cardiac mortality in the treatment of hypertension: a report from the Department of Health Hypertension Care Computing Project (DHCCP). Journal of Human Hypertension1997;11:205-11. ">DHCCP</a>; <a href="./references#CD003654-bbs2-0053" title="PahorM , GuralnikJM , CortiMC , FoleyDJ , CarboninP , HavlikRJ . Long-term survival and use of antihypertensive medications in older persons. Journal of the American Geriatrics Society1995;43(11):1191-7. ">Pahor 1995</a>; <a href="./references#CD003654-bbs2-0056" title="PsatyBM , HeckbertSR , KoepsellTD , SiscovickDS , RaghunathanTE , WeissNS , et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA1995;274:620-5. ">Psaty 1995</a>); the control group used placebo instead of other classes of antihypertensive drugs (<a href="./references#CD003654-bbs2-0033" title="ChenGJ , YangMS . The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials. PLoS ONE2013;8(3):e57854. ">Chen 2013</a>; <a href="./references#CD003654-bbs2-0059" title="GongL , ZhangW , ZhuY , ZhuJ , KongD , PagéV , et al. Shanghai trial of nifedipine in the elderly (STONE). Journal of Hypertension1996;14:1237-45. ">STONE</a>; <a href="./references#CD003654-bbs2-0060" title="LiuL , WangJG , GongL , LiuG , StaessenJA . Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. Journal of Hypertension1998;16:1823-9. ">Syst‐China</a>; <a href="./references#CD003654-bbs2-0061" title="AmeryA , BirkenhägerW , BulpittCJ , ClémentD , De LeeuwP , DolleryCT , et al. Syst-Eur: a multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging Clinical and Experimental Research1991;3:287–302. StaessenJA , FagardR , ThijsL , CelisH , ArabidzeGG , BirkenhägerWH , et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997;350:757-64. StaessenJA , ThijsL , FagardRH , BirkenhägerWH , ArabidzeG , BabeanuS , et al. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension1998;32:410-6. ">Syst‐Eur</a>); the comparison was performed between different kinds of CCBs, without any other classes of antihypertensive drugs (<a href="./references#CD003654-bbs2-0025" title="AbeM , MaruyamaN , SuzukiH , InoshitaA , YoshidaY , OkadaK , et al. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. Heart Vessels2013;28:480-9. ">Abe 2013</a>; <a href="./references#CD003654-bbs2-0045" title="KesS , CaglarN , CanberkA , DegerN , DemirtasM , DortlemezH , et al. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine. Current Medical Research and Opinion2003;19:226-37. ">Kes 2003</a>); the follow‐up was shorter than two years (<a href="./references#CD003654-bbs2-0038" title="EspinelCH , BrunerDE , DavisJR , WilliamsJL . Enalapril and verapamil in the treatment of isolated systolic hypertension in the elderly. Clinical Therapeutics1992;14:835-44. ">Espinel 1992</a>; <a href="./references#CD003654-bbs2-0041" title="The GLANT Study Group. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension - The GLANT Study. Study Group on Long-term Antihypertensive Therapy. Hypertension Research1995;18(3):235-44. ">GLANT</a>; <a href="./references#CD003654-bbs2-0042" title="GottdienerJS , RedaDJ , WilliamsDW , MatersonBJ , CushmanW , AndersonRJ . Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation1997;95:2007-14. ">Gottdiener 1997</a>; <a href="./references#CD003654-bbs2-0044" title="KereiakesDJ , ChrysantSG , Izzo JL Jr, Littlejohn T 3rd, MelinoM , LeeJ , et al. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovascular Diabetology2012;11:134. ">Kereiakes 2012</a>; <a href="./references#CD003654-bbs2-0049" title="LeonAS . Efficacy and safety of enalapril versus extended-release nifedipine for the treatment of mild-to-moderate essential hypertension: A multicenter 22-week study. Clinical Therapeutics1993;15:1094-107. ">Leon 1993</a>; <a href="./references#CD003654-bbs2-0054" title="PapademetriouV , GottdienerJS , NarayanP , CushmanWG , ZachariahPK , GottdienerPS , et al. Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. Journal of the American College of Cardiology1997;30:1802-8. ">Papademetriou 1997</a>; <a href="./references#CD003654-bbs2-0055" title="DevereuxRB , PalmieriV , SharpeN , De QuattroV , BellaJN , deSimoneG , et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation2001;104:1248-54. ">PRESERVE</a>; <a href="./references#CD003654-bbs2-0058" title="SchneiderE , JenningsA , OpieL . Captopril, nifedipine and their combination for therapy of hypertensive urgencies. South African Medical Journal1991;80(6):265-70. ">Schneider 1991</a>; <a href="./references#CD003654-bbs2-0062" title="vanLeeuwenJT , SmitAJ , MayJF , ten BergeBS , HamerHP , HavingaTK , et al. Comparative effects of diltiazem and lisinopril on left ventricular structure and filling in mild-to-moderate hypertension. Journal of Cardiovascular Pharmacology1995;26:983-9. ">Van Leeuwen 1995</a>; <a href="./references#CD003654-bbs2-0063" title="WeirMR , CassidyCA , HallPS , LancasterA , SchubertC , UrickA , et al. Efficacy and tolerability of enalapril and sustained-release verapamil in older patients with mild to moderate essential hypertension. Clinical Therapeutics1990;12:139-48. ">Weir 1990</a>; <a href="./references#CD003654-bbs2-0065" title="ZhangY , ZhangX , LiuL , WangY , TangX , ZanchettiA , et al. Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial?Journal of Hypertension2012;30:2202-12. ">Zhang 2012</a>); small sample of participants (fewer than 100 were randomised) (<a href="./references#CD003654-bbs2-0027" title="BakrisGL , CopleyJB , VicknairN , SadlerR , LeurgansS . Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney International1996;50(5):1641-50. ">Bakris 1996</a>; <a href="./references#CD003654-bbs2-0028" title="BakrisGL , MangrumA , CopleyJB , VicknairN , SadlerR . Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans. Hypertension1997;29:744-50. ">Bakris 1997</a>; <a href="./references#CD003654-bbs2-0039" title="PahorM , FranseLV , DeitcherSR , CushmanWC , JohnsonKC , ShorrRI , et al. Fosinopril versus Amlodipine Comparative Treatments Study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation2002;105:457-61. ">FACTS</a>; <a href="./references#CD003654-bbs2-0046" title="KimCJ , JoeBH . Renin-guided versus routine treatment in young untreated hypertension: a randomized comparative pilot study. Journal of Hypertension2011;29:e58-9. ">Kim 2011</a>; <a href="./references#CD003654-bbs2-0050" title="MaharajB , van derBylK . A comparison of the acute hypotensive effects of two different doses of nifedipine. American Heart Journal1992;124(3):720-5. ">Maharaj 1992</a>; <a href="./references#CD003654-bbs2-0051" title="MesciB , TekinM . Are all fixed dose combinations equally effective in blood pressure control? The analysis of four different fixed dose antihypertensive combinations. Obesity Reviews2011;12(7):568. ">Mesci 2011</a>; <a href="./references#CD003654-bbs2-0057" title="RadevskiI , SkudickyD , CandyG , SathekgeS , StrugoV , SareliP . Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. American Journal of Hypertension1999;12:194-203. ">Radevski 1999</a>); cannot make a separate comparison of CCB with other classes antihypertensive drugs because of combination drug use (<a href="./references#CD003654-bbs2-0026" title="JamersonK , WeberMA , BakrisGL , DahlöfB , PittB , ShiV , et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New England Journal of Medicine2008;359(23):2417-28. ">ACCOMPLISH</a>; <a href="./references#CD003654-bbs2-0029" title="XueC , ZhouC , YangB , LvJ , DaiB , YuS , et al. Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopril-treated hypertensive patients with chronic kidney disease: protocol for a randomised controlled trial. BMJ Open2017;7(2):e013672. ">BEAHIT</a>; <a href="./references#CD003654-bbs2-0031" title="CalhounDA , LacourcièreY , CrikelairN , JiaY , GlazerRD . Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Current Medical Research and Opinion2013;29:901-10. ">Calhoun 2013</a>; <a href="./references#CD003654-bbs2-0034" title="CiceroAF , GerocarniB , RosticciM , BorghiC . Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clinical &amp; Experimental Hypertension (New York)2012;34:113-7. ">Cicero 2012</a>; <a href="./references#CD003654-bbs2-0035" title="OgiharaT , SarutaT , RakugiH , SaitoI , ShimamotoK , MatsuokaH , et al. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. Journal of Hypertension2014;32(10):2054-63. ">COLM</a>; <a href="./references#CD003654-bbs2-0036" title="RuggenentiP , LauriaG , IlievIP , FassiA , IlievaAP , RotaS , et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension2011;58(5):776-83. ">DEMAND</a>; <a href="./references#CD003654-bbs2-0040" title="LiuL , ZhangY , LiuG , LiW , ZhangX , ZanchettiA , et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. Journal of Hypertension2005;23(12):2157-72. ">FEVER</a>; <a href="./references#CD003654-bbs2-0047" title="KojimaM , OkuboS , MizubayashiR , IsakaN , MachidaH , OkamotoS , et al. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study. Nephrology Dialysis Transplantation2013;28:1802-10. ">Kojima 2013</a>; <a href="./references#CD003654-bbs2-0048" title="LauriaG , SghirlanzoniA . Effects of manidipine and delapril on type 2 diabetic neuropathy. A randomized, double-blind, placebo-controlled trial (the DEMAND study). Journal of the Peripheral Nervous System2012;17:S30. ">Lauria 2012</a>; <a href="./references#CD003654-bbs2-0052" title="Kim-MitsuyamaS , OgawaH , MatsuiK , JinnouchiT , JinnouchiH , ArakawaK . An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney International2013;83(1):167-76. ">OSCAR</a>; <a href="./references#CD003654-bbs2-0064" title="WenW , LiyuanM , DingliangZ , ShuguangL , ShupingM , XinhuaT , al. Chinese hypertension intervention efficacy (CHIEF) study: randomized controlled trial of initial combination CCB-based antihypertensive in patients with hypertension to reduce cardiovascular events. Journal of Hypertension2011;29:e17-8. ">Wen 2011</a>); study groups differed in target BPs instead of drug classes (<a href="./references#CD003654-bbs2-0043" title="HanssonL , ZanchettiA , CarruthersSG , DahlöfB , ElmfeldtD , JuliusS , et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet1998;351:1755-62. ">HOT</a>); to avoid repeated inclusion of the research population in extended trial (<a href="./references#CD003654-bbs2-0032" title="OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J Ex</a>). </p> </section> </section> <section id="CD003654-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>Since trials with a small sample were excluded from the current review, most of included trials were large and multicentre with standardised protocols. We evaluated the methodological quality of the included trials in several ways. According to the summary assessment of the risk of bias for each important outcome (<a href="./references#CD003654-bbs2-0078" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at handbook.cochrane.org.">Higgins 2011a</a>), we assessed five trials as at low risk of bias (<a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a> <a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>; <a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>; <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>; <a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>), two trials as at high risk of bias (<a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a>; <a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a>), and the remaining 16 trials as at unclear risk of bias. The risk of bias graph (<a href="#CD003654-fig-0002">Figure 2</a>) shows judgements of the review authors about each domain presented as percentages across all included studies. The risk of bias summary (<a href="#CD003654-fig-0003">Figure 3</a>) shows review authors' judgements about each risk of bias item for each included study. </p> <div class="figure" id="CD003654-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD003654-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003654-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003654-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003654-sec-0045"> <h4 class="title">Allocation</h4> <p>All of the included studies were stated as randomised controlled trials. A computer‐generated code for randomisation was often used, but eight trials did not report the methods of allocation (<a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>; <a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>; <a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>; <a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a>; <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>; <a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>; <a href="./references#CD003654-bbs2-0023" title="RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA . Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension1997;15(11):1337-44. ZanchettiA , RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA . The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16(11):1667-76. ">VHAS</a>). Allocation concealment was seldom described; only four trials stated that their randomisation codes were concealed at the clinical trials centre (<a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>; <a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>; <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>), whilst in the <a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a> trial, an interactive voice response system for randomising, assigning, and tracking blinded medication was used. Information was insufficient to assess this 'Risk of bias' domain for the remaining trials. </p> </section> <section id="CD003654-sec-0046"> <h4 class="title">Blinding</h4> <p>All the included trials compared two first‐line antihypertensive drug classes to each other. With exception of the <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a> trial, which was open‐label, the included studies were stated as blinded. In some trials active drugs were described as of indistinguishable appearance, but it was still impossible to know the extent of blinding (<a href="./references#CD003654-bbs2-0078" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available at handbook.cochrane.org.">Higgins 2011a</a>). Nine trials used a Prospective, Randomised, Open‐label, Blinded Endpoint (PROBE) design (<a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>; <a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>; <a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>; <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a>; <a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>; <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>; <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>; <a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>), which differs from the classical double‐blind method. In a PROBE study, outcomes are evaluated by a blinded endpoint committee to avoid detection bias; in this way treatment allocation might be open to risk of performance bias from participants and doctors (<a href="./references#CD003654-bbs2-0076" title="HanssonL , HednerT , DahlöfB . Prospective Randomized Open Blinded End-point (PROBE) study. A novel design for intervention trials. Blood Pressure1992;1:113-9.">Hansson 1992</a>). </p> </section> <section id="CD003654-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>Missing data caused by loss to follow‐up or withdrawals were on the whole equal amongst the treatment groups, and an intention‐to‐treat analysis, which meant data were analysed according to randomised treatment assignments regardless of the subsequent medications (<a href="./references#CD003654-bbs2-0073" title="FergussonD , AaronS , GuyattG , HébertP . Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ2002;325:652-4.">Fergusson 2002</a>), was performed in most of the included trials, with the exception of the <a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a> trial (with negligible loss) and the <a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a> trial. Some sites and their participants were excluded after randomisation because of poor documentation of informed consent, data integrity concerns, or misconduct (<a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>; <a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>; <a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>), which could have led to attrition bias. </p> </section> <section id="CD003654-sec-0048"> <h4 class="title">Selective reporting</h4> <p>In this review, we judged all included studies to have a low risk of reporting bias.</p> </section> <section id="CD003654-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>In <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a> trial, when BP was not controlled well on monotherapy, the other study drug was added. In <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a> trial, a diuretic or blocker was added in step 3, and any other antihypertensive compound could be added as step 4 in the diltiazem group. This could have affected the evaluation of effect of each study drug.  </p> </section> </section> <section id="CD003654-sec-0050"> <h3 class="title" id="CD003654-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD003654-tbl-0001"><b>Summary of findings 1</b> CCBs versus diuretic for hypertension</a>; <a href="./full#CD003654-tbl-0002"><b>Summary of findings 2</b> CCBs versus β‐blocker for hypertension</a>; <a href="./full#CD003654-tbl-0003"><b>Summary of findings 3</b> CCBs versus ACE inhibitor for hypertension</a>; <a href="./full#CD003654-tbl-0004"><b>Summary of findings 4</b> CCBs versus ARB for hypertension</a> </p> <p>The diuretic and beta‐blocker subgroup included data from three studies in which a diuretic, a beta‐blocker, or both were used but could not be separately analysed. </p> <section id="CD003654-sec-0051"> <h4 class="title">All‐cause mortality</h4> <p>The effect of CCBs on death from any cause was not significantly different from that of any other evaluated agents: diuretics (5 trials with 35,057 participants: risk ratio (RR) 0.98, 95% confidence interval (CI) 0.92 to 1.04, I<sup>2</sup> = 0%; moderate‐certainty evidence); beta‐blockers (4 trials with 44,825 participants: RR 0.94, 95% CI 0.88 to 1.00, P = 0.54, I<sup>2</sup> = 0%; moderate‐certainty evidence); diuretics and beta‐blockers (3 trials with 31,892 participants: RR 1.03, 95% CI 0.94 to 1.12, I<sup>2</sup> = 0%; moderate‐certainty evidence); ACE inhibitors (7 trials with 27,999 participants: RR 0.97, 95% CI 0.91 to 1.03, I<sup>2</sup> = 0%; low‐certainty evidence); and ARBs (6 trials with 25,611 participants: RR 1.00, 95% CI 0.92 to 1.08, I<sup>2</sup> = 0%; moderate‐certainty evidence) (<a href="./references#CD003654-fig-0007" title="">Analysis 1.1</a>; <a href="#CD003654-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD003654-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All‐cause mortality, outcome: 1.1 CCBs versus other classes of antihypertensive agents." data-id="CD003654-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All‐cause mortality, outcome: 1.1 CCBs versus other classes of antihypertensive agents. </p> </div> </div> </div> </section> <section id="CD003654-sec-0052"> <h4 class="title">MI (non‐fatal and fatal MI plus sudden or rapid death)</h4> <p>The effect of CCBs on MI was not significantly different from that of diuretics (5 trials with 34,072 participants: RR 1.00, 95% CI 0.92 to 1.08, I<sup>2</sup> = 0%; moderate‐certainty evidence); beta‐blockers (3 trials with 22,249 participants: RR 0.90, 95% CI 0.79 to 1.02, I<sup>2</sup> = 0%; moderate‐certainty evidence); diuretics and beta‐blockers (3 trials with 31,892 participants: RR 1.05, 95% CI 0.93 to 1.19, I<sup>2</sup> = 72%; moderate‐certainty evidence); and ACE inhibitors (7 trials with 27,999 participants: RR 1.05, 95% CI 0.97 to 1.14], I<sup>2</sup> = 66%; low‐certainty evidence). The incidence of MI was statistically significantly lower (P = 0.004) for CCBs compared to ARBs (6 trials with 25,611 participants: RR 0.82, 95% CI 0.72 to 0.94, I<sup>2</sup> = 0%; moderate‐certainty evidence) (<a href="./references#CD003654-fig-0008" title="">Analysis 2.1</a>). </p> <p>We found significant statistical heterogeneity between trials comparing CCBs to diuretics and beta‐blockers (I<sup>2</sup> = 72%, P = 0.03) and CCBs to ACE inhibitors (I<sup>2</sup> = 66%, P = 0.007). A possible explanation for the heterogeneity may be that the type of CCB studied was different in each trial. The three trials involving diuretics and beta‐blockers respectively studied an aralkylamine derivative (verapamil, <a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>), a benzothiazepine derivative (diltiazem, <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>), and a DHP (felodipine, <a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>). Another possible explanation is difference in participants. In the <a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a> trial, participants diagnosed as having hypertension and who had one or more additional risk factors for cardiovascular disease were enrolled, but participants enrolled in the other two trials had no additional risk factors for cardiovascular disease. Six of seven trials involving ACE inhibitors studied DHPs, but three of them gave participants amlodipine (<a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>; <a href="./references#CD003654-bbs2-0003" title="CushmanWC , DavisBR , PresselSL , CutlerJA , EinhornPT , FordCE , et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Journal of Clinical Hypertension2012;14(1):20-31. DavisBR , CutlerJA , GordonDJ , FurbergCD , Wright JT Jr, CushmanWC , et al. Rationale and design for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). American Journal of Hypertension1996;9(4 Pt 1):342-60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288(23):2981-97. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA2002;288:2998-3007. ">ALLHAT</a>; <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a>), and two administered felodipine (<a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>), or nisoldipine (<a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>) and one gave nifedipine (<a href="./references#CD003654-bbs2-0013" title="YuiY , SumiyoshiT , KodamaK , HirayamaA , NonogiH , KanmatsuseK , et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertension Research2004;27(3):181-91. ">J‐MIC(B)</a>). One study did not describe the the specific ACE inhibitors and CCBs that were used (<a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>). The pooled RR for the trials comparing amlodipine and ACE inhibitors was 1.00 (95% CI 0.91 to 1.10, I<sup>2</sup> = 0%; low‐certainty evidence) (<a href="./references#CD003654-fig-0009" title="">Analysis 2.2</a>). </p> </section> <section id="CD003654-sec-0053"> <h4 class="title">Stroke (non‐fatal and fatal stroke)</h4> <p>The incidence of stroke was not significantly different between CCB and diuretic groups (5 trials with 34,072 participants: RR 0.94, 95% CI 0.84 to 1.05, I<sup>2</sup> = 0%; moderate‐certainty evidence) or between CCB and diuretic and beta‐blocker groups (3 trials with 31,892 participants: RR 0.92, 95% CI 0.81 to 1.03, I<sup>2</sup> = 55%; moderate‐certainty evidence). Hypertensive participants treated with CCBs had a significantly lower risk of developing a stroke than those treated with a beta‐blocker (3 trials with 22,249 participants: RR 0.77, 95% CI 0.67 to 0.88, I<sup>2</sup> = 0%; moderate‐certainty evidence) or an ACE inhibitor (7 trials with 27,999 participants: RR 0.90, 95% CI 0.81 to 0.99, I<sup>2</sup> = 28%; low‐certainty evidence). There was no difference in risk of stroke between on CCB and ARB groups (6 trials with 25611 participants: RR 0.87, 95% CI 0.76 to 1.00, p = 0.05, I<sup>2</sup> = 15%; moderate‐certainty evidence) (<a href="./references#CD003654-fig-0010" title="">Analysis 3.1</a>), but the incidence of stroke was lower for amlodipine compared to ARBs (5 trials with 23265 participants:RR 0.85, 95% CI 0.74 to 0.98, I<sup>2</sup> = 0%)(<a href="./references#CD003654-fig-0011" title="">Analysis 3.2</a>; <a href="#CD003654-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD003654-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Stroke, outcome: 3.1 CCBs versus other classes of antihypertensive agents." data-id="CD003654-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Stroke, outcome: 3.1 CCBs versus other classes of antihypertensive agents. </p> </div> </div> </div> <p>The reason for significant statistical heterogeneity between trials comparing CCBs to diuretics and beta‐blockers (I<sup>2</sup> = 55%, P = 0.11) might be related to the type of CCBs, similar to the description above in the MI results. Explanation for the heterogeneity may be that the type of CCB studied and inclusion criteria of participants were different in each trial. Regarding trials comparing CCBs to ARBs, one trial did not describe the specific CCBs used (<a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>), whilst five of six trials gave participants amlodipine (<a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>; <a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a>; <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>; <a href="./references#CD003654-bbs2-0021" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363(9426):2022-31. MannJ , JuliusS . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998;7(3):176-83. ">VALUE</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>). The pooled RR for the trials comparing amlodipine to ARBs was 0.85 (95% CI 0.74 to 0.98, I<sup>2</sup> = 0%) (<a href="./references#CD003654-fig-0011" title="">Analysis 3.2</a>). </p> </section> <section id="CD003654-sec-0054"> <h4 class="title">Congestive heart failure</h4> <p>There was no significant difference in development of congestive heart failure between CCB and beta‐blocker groups (2 trials with 19,915 participants: RR 0.83, 95% CI 0.67 to 1.04, I<sup>2</sup> = 0%; low‐certainty evidence) and between CCB and diuretic and beta‐blocker groups (3 trials with 31,892 participants: RR 1.15, 95% CI 0.99 to 1.33, I<sup>2</sup> = 0%; low‐certainty evidence). However, the risk of developing congestive heart failure was markedly higher in participants given CCBs than those given diuretics (5 trials with 34,072 participants: RR 1.37, 95% CI 1.25 to 1.51, I<sup>2</sup> = 17%; moderate‐certainty evidence); ACE inhibitors (5 trials with 25,276 participants: RR 1.16, 95% CI 1.06 to 1.28, I<sup>2</sup> = 0%; low‐certainty evidence); and ARBs (5 trials with 23,265 participants: RR 1.20, 95% CI 1.06 to 1.36, I<sup>2</sup> = 66%; low‐certainty evidence) (<a href="./references#CD003654-fig-0012" title="">Analysis 4.1</a>). </p> <p>The lack of homogeneity between the five trials comparing a CCB to an ARB may be due to the different inclusion criteria of participants: the <a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a> trial included hypertensive individuals with type 2 diabetic nephropathy, and the <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a> trial included hypertensive individuals with glucose intolerance, whilst the <a href="./references#CD003654-bbs2-0021" title="JuliusS , KjeldsenSE , WeberM , BrunnerHR , EkmanS , HanssonL , et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004;363(9426):2022-31. MannJ , JuliusS . The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure1998;7(3):176-83. ">VALUE</a>, <a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>, and <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a> trials only required participants to have hypertension and cardiovascular risk factors. There was a significant increase in congestive heart failure events among the diabetic nephropathic participants in <a href="./references#CD003654-bbs2-0010" title="BerlT , HunsickerLG , LewisJB , PfefferMA , PorushJG , RouleauJL , et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine2003;138(7):542-9. LewisEJ , HunsickerLG , ClarkeWR , BerlT , PohlMA , LewisJB , et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine2001;245(12):851-60. RodbyRA , RohdeRD , ClarkeWR , HunsickerLG , AnzaloneDA , AtkinsRC , et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation2000;15(4):487-97. ">IDNT</a> (RR 1.58, 95% CI 1.17 to 2.14) and glucose intolerance participants in <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a> (RR 5.00, 95% CI 1.46 to 17.18]) treated with a CCB compared to those treated with an ARB. </p> </section> <section id="CD003654-sec-0055"> <h4 class="title">Cardiovascular mortality</h4> <p>We added death caused by cardiovascular disease as a supplemental outcome, which differed from the published protocol, as we judged it to be important and it was reported in most of the included trials. </p> <p>We found only a marginally lower cardiovascular mortality in the CCBs group compared to the beta‐blocker group (4 trials with 44,825 participants: RR 0.90, 95% CI 0.81 to 0.99, I<sup>2</sup> = 62%; low‐certainty evidence). The effect of CCBs on cardiovascular mortality was not significantly different from that of diuretics (4 trials with 32721 participants: RR 1.02, 95% CI 0.93 to 1.12, I<sup>2</sup> = 0%; moderate‐certainty evidence); diuretics and beta‐blockers (3 trials with 31892 participants: RR 1.04, 95% CI 0.92 to 1.18, I<sup>2</sup> = 0%); ACE inhibitors (6 trials with 27619 participants: RR 0.98, 95% CI 0.89 to 1.07, I<sup>2</sup> = 0%; moderate‐certainty evidence) or ARBs (3 trials with 4642 participants: RR 0.79, 95% CI 0.54 to 1.15, I<sup>2</sup> = 0%; moderate‐certainty evidence) (<a href="./references#CD003654-fig-0013" title="">Analysis 5.1</a>) </p> <p>The heterogeneity amongst trials involving beta‐blockers (I<sup>2</sup> = 62%, P = 0.05) might be explained by the different types of CCBs that were evaluated: a non‐DHP in the <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a> trial (verapamil) and a DHP in the other three trials (amlodipine in <a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a> and <a href="./references#CD003654-bbs2-0004" title="DahlöfB , SeverPS , PoulterNR , WedelH , BeeversDG , CaulfieldM , et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906. SeverPS , DahlöfB , PoulterNR , WedelH , BeeversG , CaulfieldM , et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. Journal of Hypertension2001;19(6):1139-47. ">ASCOT‐BPLA</a>, and lacidipine in <a href="./references#CD003654-bbs2-0007" title="ZanchettiA , BondMG , HennigM , NeissA , ManciaG , Dal PalùC , et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation2002;106(19):2422-7. ">ELSA</a>). After deselecting the <a href="./references#CD003654-bbs2-0012" title="PepineCJ , HandbergEM , Cooper-DeHoffRM , MarksRG , KoweyP , MesserliFH , et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA2003;290(21):2805-16. PepineCJ , Handberg-ThurmondE , MarksRG , ConlonM , Cooper-DeHoffR , VolkersP , et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). Journal of the American College of Cardiology1998;32(5):1228-37. ">INVEST</a> trial, the pooled RR was 0.77 (95% CI 0.66 to 0.90, I<sup>2</sup> = 0%), still showing a significant decrease in cardiovascular mortality in the CCB group (<a href="./references#CD003654-fig-0014" title="">Analysis 5.2</a>). </p> </section> <section id="CD003654-sec-0056"> <h4 class="title">Major cardiovascular events (MI, congestive heart failure, stroke, and cardiovascular mortality) </h4> <p>Compared to beta‐blockers, CCBs significantly reduced major cardiovascular events (3 trials with 22,249 participants: RR 0.84, 95% CI 0.77 to 0.92, I<sup>2</sup> = 0%). In contrast, when compared to diuretics, CCBs probably increased major cardiovascular events (4 trials with 33,643 participants: RR 1.05, 95% CI 1.00 to 1.09, I<sup>2</sup> = 0%, P = 0.03). There was no significant difference in total major cardiovascular events when CCBs were compared to diuretics or beta‐blockers (2 trials with 21,011 participants: RR 1.02, 95% CI 0.95 to 1.10, I<sup>2</sup> = 0%); to ACE inhibitors (5 trials with 25,186 participants: RR 0.98, 95% CI 0.94 to 1.02, I<sup>2</sup> = 45%); or ARBs (3 trials with 6874 participants: RR 0.97, 95% CI 0.78 to 1.22, I<sup>2</sup> = 32%) (<a href="./references#CD003654-fig-0015" title="">Analysis 6.1</a>; <a href="#CD003654-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD003654-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 6 Major cardiovascular events, outcome: 6.1 CCBs versus other classes of antihypertensive agents." data-id="CD003654-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 6 Major cardiovascular events, outcome: 6.1 CCBs versus other classes of antihypertensive agents. </p> </div> </div> </div> <p>The poor methodological quality of the <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a> trial might be a source of heterogeneity amongst the five trials comparing CCBs with ACE inhibitors. We undertook a sensitivity analysis on this effect by deselecting the <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a> trial; the results were unchanged (4 trials with 24,806 participants: RR 0.98, 95% CI 0.94 to 1.02, I<sup>2</sup> = 0%) (<a href="./references#CD003654-fig-0016" title="">Analysis 6.2</a>). </p> </section> <section id="CD003654-sec-0057"> <h4 class="title">Systolic and diastolic BP reduction</h4> <p>Using the weighted mean difference method and the fixed‐effect model, we found that the mean systolic BP reduction of the CCB group was 0.81 mmHg (95% CI 0.56 to 1.06) less than that of the diuretic‐based regimen group, and 3.00 mmHg (95% CI 2.59 to 3.41) less than the diuretic‐and‐beta‐blocker‐based regimen group. Systolic BP reduction was ‐1.11 mmHg (95% CI −1.40 to −0.82) more with CCBs than with ACE inhibitors, and ‐2.10 mmHg (95% CI −2.46 to −1.74]) more than with ARBs. There was no significant difference between the CCB group and beta‐blocker group (P = 0.38), or between the CCB group and alpha‐1‐antagonist group (P = 0.27) (<a href="./references#CD003654-fig-0017" title="">Analysis 7.1</a>). </p> <p>For diastolic BP, the mean reduction of the CCB group was −0.68 mmHg (95% CI −0.84 to −0.52) more than the diuretic group; −0.63 mmHg (95% CI −0.81 to −0.44) more than the ACE inhibitor group; −1.70 mmHg (95% CI −1.91 to −1.49) more than the ARB group; and −1.20 mmHg (95% CI −2.39 to −0.01) more than the alpha‐1‐antagonist group. Mean diastolic changes between the CCB and beta‐blocker groups were not significantly different (<a href="./references#CD003654-fig-0018" title="">Analysis 7.2</a>). </p> <p>There was heterogeneity (I<sup>2</sup> of 85%) for the four trials comparing the effect of CCBs versus ACE inhibitors on systolic BP reduction, however there was no heterogeneity for the same comparison evaluating diastolic BP reduction. The heterogeneity was most likely due to the poor methodological quality of the <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a> trial. Sensitivity analyses conducted without the <a href="./references#CD003654-bbs2-0008" title="TattiP , PahorM , ByingtonRP , Di MauroP , GuariscoR , StrolloG , et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care1998;21(4):597-603. ">FACET</a> trial resulted in homogeneous significant mean differences for both systolic and diastolic BP: mean difference −1.00 (95% CI −1.29 to −0.70) and −0.62 (95% CI −0.81 to −0.44), respectively (<a href="./references#CD003654-fig-0019" title="">Analysis 7.3</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003654-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003654-sec-0058"></div> <section id="CD003654-sec-0059"> <h3 class="title" id="CD003654-sec-0059">Summary of main results</h3> <p>After a systematic search and selection process according to the protocol for this review, we included 23 RCTs with 153,849 participants that assessed cardiovascular outcomes or BP change, or both, among hypertensive participants. The two most important outcomes from the perspective of the patient were total all‐cause mortality and major cardiovascular events. The latter outcome is important as it is a composite of the individual outcomes of stroke, MI, and congestive heart failure. There was no significant difference between first‐line CCBs and any of the other classes of antihypertensive drugs for total mortality. In this update, no new trial comparing CCBs with beta‐blockers or diuretics has been incorporated, therefore the outcomes for these comparisons are consistent with the first version of the review. First‐line CCBs reduced major cardiovascular events as compared to beta‐blockers (moderate‐certainty evidence) and increased major cardiovascular events as compared to diuretics (moderate‐certainty evidence). The reduction in major cardiovascular events with CCBs as compared to beta‐blockers is explained by a significant reduction in stroke (moderate‐certainty evidence) and cardiovascular mortality (low‐certainty evidence). The increase in major cardiovascular events for first‐line CCBs as compared to diuretics is explained by increased congestive heart failure events (moderate‐certainty evidence). The risk difference (RD) for heart failure for the comparison of CCBs versus diuretics was 0.02 and is thus clinically important and consistent with either a protective effect of diuretics or a harmful effect of CCBs for this outcome. The finding that first‐line CCBs increased congestive heart failure as compared to ACE inhibitors (low‐certainty evidence) and ARBs (low‐certainty evidence) is robust after more RCTs were included in this update. The other significant differences found were that first‐line CCBs reduced stroke more than ACE inhibitors (low‐certainty evidence) and reduced MI more than ARBs (moderate‐certainty evidence). With the inclusion of new studies comparing CCBs with ARBs, the advantages of CCBs in reducing stroke over ARBs that were found in the first version of the review no longer exist (<a href="./full#CD003654-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD003654-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD003654-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD003654-tbl-0004">summary of findings Table 4</a>), but in pooled analysis, the incidence of stroke was lower for amlodipine compared to ARBs.(<a href="./references#CD003654-fig-0011" title="">Analysis 3.2</a>) </p> <p>Blood pressures decreased in all treatment arms of all the included trials, but mean BP reduction differed. First‐line CCB‐based regimens lowered systolic BP less than first‐line diuretic‐based regimens and conventional treatment‐based regimens. In contrast, first‐line CCBs lowered diastolic BP better than diuretic‐based regimens. First‐line CCB‐based regimens also lowered both systolic and diastolic BPs more than ACE inhibitors and ARBs. This could partially explain the differences in stroke outcomes. </p> </section> <section id="CD003654-sec-0060"> <h3 class="title" id="CD003654-sec-0060">Overall completeness and applicability of evidence</h3> <p>Most of the included trials with the exception of <a href="./references#CD003654-bbs2-0020" title="MascioliSR , Grimm RH Jr, NeatonJD , StamlerJ , PrineasRJ , CutlerJA , et al. The Treatment of Mild Hypertension Study (TOMHS): characteristics of participants at baseline. American Journal of Cardiology1990;66(9):32C-5C. NeatonJD , Grimm RH Jr, PrineasRJ , StamlerJ , GranditsGA , ElmerPJ , et al. Treatment of Mild Hypertension Study: final results. JAMA1993;270:713-24. StamlerJ , PrineasRJ , NeatonJD , GrimmRH , McDonaldRH , SchnaperHW , et al. Background and design of the new US trial on diet and drug treatment of 'mild' hypertension (TOMHS). American Journal of Cardiology1987;59(14):51G-60G. The Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Archives of Internal Medicine1991;151:1413-23. ">TOMHS</a> reported relevant hypertension outcomes, but not all of the desired outcomes were available from each trial. Furthermore, supplemental inclusion criteria were required in several trials, and most trials were event‐driven hypertension studies, which meant that the included participants tended to have more complicated hypertension or advanced disease (<a href="./references#CD003654-bbs2-0101" title="ZanchettiA . Evidence-based medicine in hypertension: what type of evidence?Journal of Hypertension2005;23:1113-20.">Zanchetti 2005</a>). Patients at the two extremes, that is those with uncomplicated hypertension at one extreme and those with severe or acute hypertension and secondary hypertension at the other extreme, were not included in the current analysis. </p> <p>Although we included 23 studies with a large number of participants comparing several classes of antihypertensive drugs in this update, the number of trials for each of the subgroups was limited. Because of this data were insufficient for some comparisons. This was particularly the case for alpha‐1‐antagonists. Furthermore, most of the included CCBs were dihydropyridines, with evidence for non‐DHPs inadequate. </p> <p>The prevalence of hypertension amongst adults with diabetes mellitus is approximately 80% (<a href="./references#CD003654-bbs2-0081" title="KannelWB , WilsonPW , ZhangTJ . The epidemiology of impaired glucose tolerance and hypertension. American Heart Journal1991;121:1268-73.">Kannel 1991</a>). Although all major antihypertensive drug classes (i.e. ACE inhibitors, ARBs, CCBs, and diuretics) are useful in the treatment of hypertension in diabetes mellitus (<a href="./references#CD003654-bbs2-0096" title="WheltonPK , CareyRM , AronowWS , Casey DE Jr, CollinsKJ , Dennison HimmelfarbC , et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension2018;71(6):1269-324.">Whelton 2018</a>), guidelines recommended CCBs as a first‐line choice for those with hypertension and diabetes (<a href="./references#CD003654-bbs2-0080" title="JamesPA , OparilS , CarterBL , CushmanWC , Dennison-HimmelfarbC , HandlerJ , et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA2014;311(5):507-20.">JNC‐8</a>; <a href="./references#CD003654-bbs2-0096" title="WheltonPK , CareyRM , AronowWS , Casey DE Jr, CollinsKJ , Dennison HimmelfarbC , et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension2018;71(6):1269-324.">Whelton 2018</a>; <a href="./references#CD003654-bbs2-0097" title="WilliamsB , ManciaG , SpieringW , Agabiti RoseiE , AziziM , BurnierM , et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal2018;39(33):3021-104.">Williams 2018</a>). Opie and colleagues made the point that the incidence of developing diabetes was less on the amlodipine‐based regimen (<a href="./references#CD003654-bbs2-0085" title="OpieLH , SchallR . Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. Journal of the American College of Cardiology2002;39:315-22.">Opie 2002</a>). On the other hand, the <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a> study found that hypertensive participants with type 2 diabetes mellitus or impaired glucose tolerance in the valsartan group had a significantly lower incidence of heart failure than those in the amlodipine group. A meta‐analysis of RCTs of primary prevention of albuminuria in participants with diabetes mellitus demonstrated a significant reduction in progression of moderately to severely increased albuminuria with the use of ACE inhibitors or ARBs (<a href="./references#CD003654-bbs2-0086" title="PalmerSC , MavridisD , NavareseE , CraigJC , TonelliM , SalantiG , et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet2015;385(9982):2047-56.">Palmer 2015</a>), with CCB showing no effect. As we were unable to extract data to separately evaluate the effects on hypertensive participants with diabetes in our review, it is not possible to say whether CCBs have different effects in diabetic hypertensive patients. </p> </section> <section id="CD003654-sec-0061"> <h3 class="title" id="CD003654-sec-0061">Quality of the evidence</h3> <p>We graded the overall quality of the evidence and developed 'Summary of findings'  tables, using GRADEpro GDTsoftware. </p> <p>We found moderate‐certainty evidence that all‐cause mortality was not different between first‐line CCBs and any other antihypertensive classes. </p> <p>We found moderate‐certainty evidence that first‐line CCBs increased congestive heart failure more than diuretics, and low‐certainty evidence that they increased congestive heart failure more than ACE inhibitors or ARBs. </p> <p>We found moderate‐certainty evidence that first‐line CCBs reduced stroke, and low‐certainty evidence that they reduced  cardiovascular mortality more than beta‐blockers. </p> <p>We found low‐certainty evidence that first‐line CCBs reduced  stroke more than ACE inhibitors, and moderate‐certainty evidence that they reduced myocardial infarction more than ARBs. </p> </section> <section id="CD003654-sec-0062"> <h3 class="title" id="CD003654-sec-0062">Potential biases in the review process</h3> <p>The included trials varied in their designs and methods, baseline and goal BPs, study populations, and drugs, so combining their data to arrive at a conclusion may have some limitations. For example, CCBs are a heterogeneous group of drugs that are subclassified into DHPs and non‐DHPs. The different classes have different in binding sites on the calcium channel pores and thus could have different effects (<a href="./references#CD003654-bbs2-0084" title="OpieLH , YusufS , KüblerW . Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Progress in Cardiovascular Diseases2000;43:171-96.">Opie 2000</a>; <a href="./references#CD003654-bbs2-0093" title="TriggleDJ . Calcium channel antagonists: clinical uses - past, present and future. Biochemical Pharmacology2007;74:1-9.">Triggle 2007</a>). In the current review, we did not evaluate different types of CCBs in separate comparisons, but it might not be appropriate to combine them in a meta‐analysis. The high I<sup>2</sup> values for pooled trials involving both DHPs and non‐DHPs (72% for three trials assessing MI events) are consistent with this possibility (<a href="./references#CD003654-bbs2-0006" title="BlackHR , ElliottWJ , GranditsG , GrambschP , LucenteT , WhiteWB , et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA2003;289(16):2073-82. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension2001;37(1):12-8. BlackHR , ElliottWJ , NeatonJD , GranditsG , GrambschP , Grimm RH Jr, et al. Rationale and design for the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Controlled Clinical Trials1998;19(4):370-90. ">CONVINCE</a>; <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>; <a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>). However, in this case dividing the trials into DHPs and non‐DHPs does not explain the heterogeneity. Likewise, heterogenous populations in the included trials might be the cause of the heterogeneity of the effect. In the current review, enrolled participants included those with diabetes, cardiovascular disease, kidney disease, or other conditions. It was not possible to investigate the effect of these subgroup populations on the effect size. In general, there was excellent homogeneity of most effects as shown by an I<sup>2</sup> value of 0%, with only a few outcomes associated with I<sup>2</sup> &gt; 50%, leading us to believe that the overall conclusions of our review are valid. </p> <p>Although the benefits of BP lowering for the prevention of cardiovascular disease are well established (<a href="./references#CD003654-bbs2-0068" title="Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet2000;356:1955-64.">BPLTTC 2000</a>; <a href="./references#CD003654-bbs2-0069" title="Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet2003;362:1527-35.">BPLTTC 2003</a>; <a href="./references#CD003654-bbs2-0072" title="EzzatiM , LopezAD , RodgersA , Vander HoornS , MurrayCJ , Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002 Nov 2;360(9343):1347-60.">Ezzati 2002</a>; <a href="./references#CD003654-bbs2-0092" title="ThomopoulosC , ParatiG , ZanchettiA . Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses. Journal of Hypertension2015;33(2):195-211.">Thomopoulos 2015</a>; <a href="./references#CD003654-bbs2-0099" title="WrightJM , MusiniVM . First-line drugs for hypertension. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD001841. [DOI: 10.1002/14651858.CD001841.pub3]">Wright 2018</a>; <a href="./references#CD003654-bbs2-0100" title="XieX , AtkinsE , LvJ , BennettA , NealB , NinomiyaT , et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet2016;387(10017):435-43.">Xie 2016</a>), which antihypertensive drug class should be prescribed first is still somewhat controversial. In order to achieve the BP goal many patients need to be prescribed more than one antihypertensive agent (<a href="./references#CD003654-bbs2-0071" title="ChobanianAV , BakrisGL , BlackHR , CushmanWC , GreenLA , Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension2003;42:1206-52.">Chobanian 2003</a>; <a href="./references#CD003654-bbs2-0075" title="HallerH . Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. International Journal of Clinical Practice2008;62:781-90.">Haller 2008</a>; <a href="./references#CD003654-bbs2-0083" title="ManciaG , De BackerG , DominiczakA , CifkovaR , FagardR , GermanoG , et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal2007;28(12):1462-536.">Mancia 2007</a>). This fact leads to another limitation in the review and is perhaps its major weakness. Since additional antihypertensive agents other than first‐line drugs were administered sequentially to reach BP goals in most of the included trials, the results may have been confounded, although they were presumed to reflect the effect of the first drug. Only one small trial included in our review prohibited the use of any other antihypertensive drugs (<a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a>), and it concluded that the CCB and diuretic groups had a similar decrease in BPs and cardiovascular events. BP differences between different classes of drugs could have an impact on outcomes (<a href="./references#CD003654-bbs2-0091" title="StaessenJA , WangJG , ThijsL . Cardiovascular prevention and blood pressure reduction: a quantitative overview. Journal of Hypertension2003;21:1055-76.">Staessen 2003</a>; <a href="./references#CD003654-bbs2-0099" title="WrightJM , MusiniVM . First-line drugs for hypertension. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD001841. [DOI: 10.1002/14651858.CD001841.pub3]">Wright 2018</a>), which is a further limitation of this type of review. In addition, three included trials had a 2 X 3 design (<a href="./references#CD003654-bbs2-0001" title="AgodoaLY , AppelL , BakrisGL , BeckG , BourgoignieJ , BriggsJP , et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA2001;285(21):2719-28. KusekJW , LeeJY , SmithDE , MilliganS , FaulknerM , CornellCE , et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials1996;16:40S-6S. NorrisK , BourgoigneJ , GassmanJ , HebertL , MiddletonJ , PhillipsRA , et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. American Journal of Kidney Diseases2006;48(5):739-51. WrightJT , BakrisG , GreeneT , AgodoaLY , AppelLJ , CharlestonJ , et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002;288(19):2421-31. WrightJT , KusekJW , TotoRD , LeeJY , AgodoaLY , KirkKA , et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Controlled Clinical Trials1996;17(4 Suppl):3S-16S. ">AASK</a>; <a href="./references#CD003654-bbs2-0002" title="EstacioRO , JeffersBW , HiattWR , BiggerstaffSL , GiffordN , SchrierRW , et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine1998;338(10):645-52. SavageS , Johnson NagelN , EstacioRO , FeigPU , MacCarthyEP , LukkenNJ , et al. The ABCD (Appropriate Blood Pressure Control in Diabetes) trial: rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online Journal of Current Clinical Trials 1993 Nov 24:Doc No 104. SchrierR , EstacioR . Additional follow-up from the ABCD Trial in Patients with Type 2 Diabetes and Hypertension. New England Journal of Medicine2000;343:1969. ">ABCD</a>; <a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>). Participants were randomised 1) BP tight target versus usual 2) different drug classes. As reported, the effect of different drugs is difficult to differentiate from that of BP targets. </p> <p>We have tried to reduce the risk of attrition bias by reporting on the intent‐to‐treat population to the greatest degree possible. We do not think publication bias is likely as we have done an extensive search of the pertinent literature, including published and unpublished studies, without any language restrictions. </p> </section> <section id="CD003654-sec-0063"> <h3 class="title" id="CD003654-sec-0063">Agreements and disagreements with other studies or reviews</h3> <p>This review was not designed to assess the effect of CCBs versus placebo or no treatment, but other meta‐analyses have addressed this question and demonstrated that first‐line CCBs reduce stroke and total cardiovascular events. A recent meta‐analysis of 10 RCTs (30, 359 participants) comparing CCBs blood pressure‐lowering treatment with no or less intense treatment showed that significant reductions in stroke, major cardiovascular events, cardiovascular and all‐cause death were obtained with CCBs (<a href="./references#CD003654-bbs2-0092" title="ThomopoulosC , ParatiG , ZanchettiA . Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses. Journal of Hypertension2015;33(2):195-211.">Thomopoulos 2015</a>). Another meta‐analysis of 147 RCTs including 464,000 participants with hypertension demonstrated that all major antihypertensive drug classes (diuretics, ACE inhibitors, ARBs, beta‐blockers, and CCBs) caused a similar reduction in coronary heart disease events and stroke for a given reduction in BP (<a href="./references#CD003654-bbs2-0082" title="LawMR , MorrisJK , WaldNJ . Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ2009;338:b1665.">Law 2009</a>). Blood pressure lowering by all classes of antihypertensive drugs is accompanied by significant reductions in stroke and major cardiovascular events, supporting the concept that reduction of these events is due to BP lowering. </p> <p>In this review, we found that CCBs increased total cardiovascular events as compared to diuretics; within total cardiovascular events, only congestive heart failure events increased with CCB. The results of recent meta‐analyses are consistent with this conclusion: thiazides were associated with a lower risk of heart failure compared with CCBs, whilst there was no difference between groups in other events (<a href="./references#CD003654-bbs2-0087" title="ReboussinDM , AllenNB , GriswoldME , GuallarE , HongY , LacklandDT , et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2017 Nov 13 [Epub ahead of print]. [DOI: 10.1161/HYP.0000000000000067]">Reboussin 2017</a>; <a href="./references#CD003654-bbs2-0092" title="ThomopoulosC , ParatiG , ZanchettiA . Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses. Journal of Hypertension2015;33(2):195-211.">Thomopoulos 2015</a>). The increase in total cardiovascular events for first‐line CCBs as compared to diuretics is explained by increased congestive heart failure events with CCBs. </p> <p>CCBs significantly increased the risk of congestive heart failure as compared to diuretics, ACE inhibitors, and ARBs. This finding is consistent with other reviews (<a href="./references#CD003654-bbs2-0067" title="BlackHR . Calcium channel blockers in the treatment of hypertension and prevention of cardiovascular disease: results from major clinical trials. Clinical Cornerstone2004;6(4):53-66.">Black 2004</a>; <a href="./references#CD003654-bbs2-0084" title="OpieLH , YusufS , KüblerW . Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Progress in Cardiovascular Diseases2000;43:171-96.">Opie 2000</a>; <a href="./references#CD003654-bbs2-0092" title="ThomopoulosC , ParatiG , ZanchettiA . Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses. Journal of Hypertension2015;33(2):195-211.">Thomopoulos 2015</a>). The Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults indicated that thiazides were associated with a lower risk of many cardiovascular outcomes compared with other antihypertensive drug classes (<a href="./references#CD003654-bbs2-0087" title="ReboussinDM , AllenNB , GriswoldME , GuallarE , HongY , LacklandDT , et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2017 Nov 13 [Epub ahead of print]. [DOI: 10.1161/HYP.0000000000000067]">Reboussin 2017</a>). Since CCBs and other drug classes did not have any other advantages as compared to diuretics, this would suggest that diuretics are the preferred first‐line drugs for patients with hypertension. </p> <p>The results of this review are consistent with the findings of another Cochrane Review evaluating the comparison of beta‐blockers versus first‐line CCBs (<a href="./references#CD003654-bbs2-0098" title="WiysongeCS , BradleyHA , VolminkJ , MayosiBM , OpieLH . Beta-blockers for hypertension. Cochrane Database of Systematic Reviews2007, Issue 1. Art. No: CD002003. [DOI: 10.1002/14651858.CD002003.pub2]">Wiysonge 2007</a>). That review concluded that beta‐blockers reduced total cardiovascular events significantly less than CCBs. A similar meta‐analysis including six of the trials included in our review, <a href="./references#CD003654-bbs2-0011" title="BrownMJ , PalmerCR , CastaigneA , deLeeuwPW , ManciaG , RosenthalT , et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet2000;356(9227):366-72. ">INSIGHT</a>; <a href="./references#CD003654-bbs2-0014" title="BorhaniNO , MercuriM , BorhaniPA , BuckalewVM , Canossa-TerrisM , CarrAA , et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA1996;276(10):785-91. BorhaniNO , MillerST , BruggerSB , SchnaperHW , CravenTE , BondMG , et al. MIDAS: hypertension and atherosclerosis, a trial of the effect of antihypertensive drug treatment on atherosclerosis. Journal of Cardiovascular Pharmacology1992;19(Suppl 3):16-20. FurbergC , ByingtonR , BorhaniN . Design features: Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). American Journal of Medicine1989;86(Suppl 4A):37-9. ">MIDAS</a>; <a href="./references#CD003654-bbs2-0016" title="KuramotoK , National Intervention Cooperative Study Group. Treatment of elderly hypertensive in Japan: National Intervention Cooperative Study in Elderly Hypertensives. Journal of Hypertension1994;12(Suppl 6):S35-40. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension1999;34(5):1129-33. ">NICS‐EH</a>; <a href="./references#CD003654-bbs2-0017" title="HanssonL , HednerT , Lund-JohansenP , KjeldsenSE , LindholmLH , SyvertsenJO , et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet2000;356:359-65. HednerT . Progress report on the Nordic diltiazem study (NORDIL): an outcome study in hypertensive patients. Blood Pressure1999;8(5-6):296-9. NORDIL Study Group. The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure1993;2:312-21. ">NORDIL</a>; <a href="./references#CD003654-bbs2-0019" title='DahlöfB , HanssonL , LindholmLH , SchersténB , WesterPO , EkbomT , et al. STOP-Hypertension-2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Pressure1993;2:136-41. HanssonL , LindholmLH , EkbomT , DahlöfB , LankeJ , SchersténB , et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet1999;354:1751-6. LindholmLH , HanssonL , DahlöfB , EkbomT , HednerT , De FaireU , et al. The Swedish Trial in Old Patients with Hypertension (STOP-Hypertension-2): a progress report. Blood Pressure1996;5:300-4. '>STOP‐Hypertension‐2</a>; <a href="./references#CD003654-bbs2-0023" title="RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA , ZanchettiA . Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. Journal of Hypertension1997;15(11):1337-44. ZanchettiA , RoseiEA , Dal PalùC , LeonettiG , MagnaniB , PessinaA . The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension1998;16(11):1667-76. ">VHAS</a>, concluded that mortality and major cardiovascular events with CCBs were similar to those seen with conventional therapy (diuretics or beta‐blockers) (<a href="./references#CD003654-bbs2-0085" title="OpieLH , SchallR . Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. Journal of the American College of Cardiology2002;39:315-22.">Opie 2002</a>). A recent meta‐analysis showed that the risk of stroke was significantly higher (25%) with beta‐blockers as compared with CCBs (<a href="./references#CD003654-bbs2-0092" title="ThomopoulosC , ParatiG , ZanchettiA . Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses. Journal of Hypertension2015;33(2):195-211.">Thomopoulos 2015</a>). To this point there is no evidence to support the initial use of beta‐blockers for hypertension in the absence of specific cardiovascular comorbidities. </p> <p>Other authors have claimed that CCBs are more effective than other treatments in decreasing the risk of stroke in hypertensive individuals (<a href="./references#CD003654-bbs2-0066" title="AngeliF , VerdecchiaP , ReboldiGP , GattobigioR , BentivoglioM , StaessenJA , et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. American Journal of Hypertension2004;17:817-22.">Angeli 2004</a>; <a href="./references#CD003654-bbs2-0095" title="VerdecchiaP , ReboldiG , AngeliF , GattobigioR , BentivoglioM , ThijsL , et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension2005;46:386-92.">Verdecchia 2005</a>). However, a previous meta‐analysis found no difference between ARBs and CCBs in risk of stroke in diabetic participants (<a href="./references#CD003654-bbs2-0094" title="TurnbullF , NealB , AlgertC , ChalmersJ , ChapmanN , CutlerJ , et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Archives of Internal Medicine2005;165(12):1410-9.">Turnbull 2005</a>). Our results showed that stroke events are significantly reduced by CCBs as compared to beta‐blockers and ACE inhibitors. In the previous version of this review we found that CCBs reduced the risk of stroke as compared to ARBs (2 trials with 16,391 participants). In this updated version we added 4 new trials for comparison (<a href="./references#CD003654-bbs2-0005" title="FukuiT , RahmanM , HayashiK , TakedaK , HigakiJ , SatoT , et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. Hypertension Research2003;26(12):979-90. OgiharaT , NakaoK , FukuiT , FukiyamaK , UeshimaK , ObaK , et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension2008;51(2):393-8. OgiharaT , UeshimaK , NakaoK , FukiyamaK , ObaK , YasunoS , et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertension Research2011;34(12):1295-301. ">CASE‐J</a>; <a href="./references#CD003654-bbs2-0009" title="AsayamaK , OhkuboT , MetokiH , ObaraT , InoueR , KikuyaM , et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertension Research2012;35(11):1102-10. ">HOMED‐BP</a>; <a href="./references#CD003654-bbs2-0015" title="MatsushitaK , MuramatsuT , KondoT , MaedaK , ShintaniS , MuroharaT , et al. Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. Journal of Cardiology2010;56(1):111-7. MuramatsuT , MatsushitaK , YamashitaK , KondoT , MaedaK , ShintaniS , et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study. Hypertension2012;59(3):580-6. ">NAGOYA</a>; <a href="./references#CD003654-bbs2-0022" title="NarumiH , TakanoH , ShindoS , FujitaM , MizumaH , KuwabaraY , et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertension Research2011;34(1):62-9. ">VART</a>),the results indicated no difference between ARBs and CCBs(total 6 trials with 25611 participants). But in a pooled analysis of 5 trials comparing amlodipine of CCBs and ARBs, the incidence of stroke was lower for amlodipine compared to ARBs.This may be due to the greater blood pressure‐lowering effect of CCBs as compared to ACE inhibitors as was found in this review, but it does not explain the difference for beta‐blockers, which did not have a different blood pressure‐lowering effect. It has been hypothesised that CCBs might have anti‐atherosclerotic actions that could be helpful in reducing stroke as well (<a href="./references#CD003654-bbs2-0066" title="AngeliF , VerdecchiaP , ReboldiGP , GattobigioR , BentivoglioM , StaessenJA , et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. American Journal of Hypertension2004;17:817-22.">Angeli 2004</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003654-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003654-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD003654-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003654-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All‐cause mortality, outcome: 1.1 CCBs versus other classes of antihypertensive agents." data-id="CD003654-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All‐cause mortality, outcome: 1.1 CCBs versus other classes of antihypertensive agents. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Stroke, outcome: 3.1 CCBs versus other classes of antihypertensive agents." data-id="CD003654-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Stroke, outcome: 3.1 CCBs versus other classes of antihypertensive agents. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 6 Major cardiovascular events, outcome: 6.1 CCBs versus other classes of antihypertensive agents." data-id="CD003654-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 6 Major cardiovascular events, outcome: 6.1 CCBs versus other classes of antihypertensive agents. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: All‐cause mortality, Outcome 1: CCBs vs other classes of antihypertensive agents" data-id="CD003654-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: All‐cause mortality, Outcome 1: CCBs vs other classes of antihypertensive agents </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Myocardial infarction, Outcome 1: CCBs vs other classes of antihypertensive agents" data-id="CD003654-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Myocardial infarction, Outcome 1: CCBs vs other classes of antihypertensive agents </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Myocardial infarction, Outcome 2: Amlodipine vs ACE inhibitors" data-id="CD003654-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Myocardial infarction, Outcome 2: Amlodipine vs ACE inhibitors</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Stroke, Outcome 1: CCBs vs other classes of antihypertensive agents" data-id="CD003654-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Stroke, Outcome 1: CCBs vs other classes of antihypertensive agents</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Stroke, Outcome 2: Amlodipine vs ARBs" data-id="CD003654-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Stroke, Outcome 2: Amlodipine vs ARBs</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Congestive heart failure, Outcome 1: CCBs vs other classes of antihypertensive agents" data-id="CD003654-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Congestive heart failure, Outcome 1: CCBs vs other classes of antihypertensive agents </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cardiovascular mortality, Outcome 1: CCBs vs other classes of antihypertensive agents" data-id="CD003654-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Cardiovascular mortality, Outcome 1: CCBs vs other classes of antihypertensive agents </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Cardiovascular mortality, Outcome 2: DHP vs β‐blockers" data-id="CD003654-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Cardiovascular mortality, Outcome 2: DHP vs β‐blockers</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Major cardiovascular events, Outcome 1: CCBs vs other classes of antihypertensive agents" data-id="CD003654-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Major cardiovascular events, Outcome 1: CCBs vs other classes of antihypertensive agents </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Major cardiovascular events, Outcome 2: Sensitivity analysis: CCBs vs ACE inhibitors" data-id="CD003654-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Major cardiovascular events, Outcome 2: Sensitivity analysis: CCBs vs ACE inhibitors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Blood pressure reduction, Outcome 1: Systolic blood pressure reduction" data-id="CD003654-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Blood pressure reduction, Outcome 1: Systolic blood pressure reduction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Blood pressure reduction, Outcome 2: Diastolic blood pressure reduction" data-id="CD003654-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Blood pressure reduction, Outcome 2: Diastolic blood pressure reduction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003654-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/urn:x-wiley:14651858:media:CD003654:CD003654-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Blood pressure reduction, Outcome 3: Sensitivity analysis: CCBs vs ACE inhibitors" data-id="CD003654-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_t/tCD003654-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Blood pressure reduction, Outcome 3: Sensitivity analysis: CCBs vs ACE inhibitors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/media/CDSR/CD003654/image_n/nCD003654-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003654-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">CCBs versus diuretic for hypertension</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CCBs versus diuretic for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with hypertension<br/><b>Settings:</b> outpatients or inpatients<br/><b>Intervention:</b> CCBs versus diuretic<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CCBs versus diuretic</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 2 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98 </b><br/>(0.92 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35,057<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNH 83 (95%CI 53 to 187)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b><br/>(111 to 126) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00 </b><br/>(0.92 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,072<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 146 (95%CI 81 to 729)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b><br/>(68 to 79) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94 </b><br/>(0.84 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,072<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 236 (95%CI 120 to 5816)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b><br/>(33 to 42) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Congestive heart failure</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.37 </b><br/>(1.25 to 1.51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>34,072<br/>(5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNH 107 (95% CI 71 to 213)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b><br/>(56 to 68) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular mortality</b><br/>Follow‐up: 2 to 5 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.02 </b><br/>(0.93 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32,721<br/>(4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 242 (95% CI 111 to 1377)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(50 to 60) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>  </p> <p><b>CCB:</b> calcium channel blocker; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>NNH:</b> number needed to harm; <b>NNT:</b> number needed to treat </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate.<br/>  </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>All studies were blinded, but two of them did not describe the method of blinding. All studies mentioned randomisation, but only three studies provided details; only one study described allocation concealment.<br/><sup>2</sup>All studies were blinded, but one of them did not describe the method of blinding. All studies mentioned randomisation, but two of them did not provide details; only one study described allocation concealment.<br/><sup>3</sup>All four studies were blinded, but one of them did not describe the method of blinding. All studies mentioned randomisation, but two of them did not provide details; only one study described allocation concealment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">CCBs versus diuretic for hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003654-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CCBs versus β‐blocker for hypertension</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CCBs versus β‐blocker for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with hypertension<br/><b>Settings:</b> outpatients or inpatients<br/><b>Intervention:</b> CCBs versus β‐blocker </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CCBs versus β‐blocker</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 2.7 to 5.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94</b> <br/>(0.88 to 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44,825<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 194 (95%CI 99 to 4004)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>79 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b><br/>(70 to 79) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.90</b> <br/>(0.79 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22,249<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 223 (95%CI 102 to 1190)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b><br/>(36 to 46) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.77</b> <br/>(0.67 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22,249<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 104 (95%CI 69 to 210)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b><br/>(27 to 36) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Congestive heart failure</b><br/>Follow‐up: 4 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.83</b> <br/>(0.67 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>19,915<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 279 (95%CI 141 to 12238)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><br/>(12 to 19) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular mortality</b><br/>Follow‐up: 2.7 to 5.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.90</b> <br/>(0.81 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44,825<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 279 (95%CI 145 to 3783)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b><br/>(29 to 35) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CCB:</b> calcium channel blocker; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>NNT:</b> number needed to treat </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Only two studies described allocation concealment.<br/><sup>2</sup>Two studies did not describe allocation concealment.<br/><sup>3</sup>Wide 95% CI crossing the line of no effect and low event rate.<br/><sup>4</sup>I<sup>2</sup> &gt; 60%. Effect size varied considerably. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">CCBs versus β‐blocker for hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003654-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CCBs versus ACE inhibitor for hypertension</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CCBs versus ACE inhibitor for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with hypertension<br/><b>Settings:</b> outpatients or inpatients<br/><b>Intervention:</b> CCBs versus ACE inhibitor </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CCBs versus ACE inhibitor</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.97</b> <br/>(0.91 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27,999<br/>(7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 282 (95%CI 89 to 240)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>122 per 1000</b><br/>(115 to 130) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction</b><br/>Follow‐up: 3 to 5.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b> <br/>(0.97 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27,999<br/>(7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 235 (95%CI 96 to 541)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b><br/>(69 to 81) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/>Follow‐up: 3 to 5.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.90</b> <br/>(0.81 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27,999<br/>(7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 185 (95%CI 95 to 2863)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b><br/>(42 to 51) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Congestive heart failure</b><br/>Follow‐up: median 3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.16</b> <br/>(1.06 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25,276<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>4,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 94 (95%CI 59 to 222)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b><br/>(66 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular mortality</b><br/>Follow‐up: 3 to 5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.98</b> <br/>(0.89 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>27,619<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 923 (95%CI 148 to 219)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b><br/>(55 to 66) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ACE:</b> angiotensin‐converting enzyme; <b>CCB:</b> calcium channel blocker; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>NNT:</b> number needed to treat </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>In one study, study drugs were administered open‐label. All studies mentioned randomisation, but two of them did not provide details; only three studies described allocation concealment.<br/><sup>2</sup>In one study, when BP was not well‐controlled on monotherapy, the other study drug was added.<br/><sup>3</sup>I<sup>2</sup> &gt; 60%; direction and size of effect inconsistent.<br/><sup>4</sup>All studies mentioned randomisation, but two of them did not provide details; only two studies described allocation concealment.<br/><sup>5</sup>Wide 95% CI crossing the line of no effect and low event rate.<br/><sup>6</sup>All studies mentioned randomisation, but two of them did not provide details; only three studies described allocation concealment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">CCBs versus ACE inhibitor for hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003654-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">CCBs versus ARB for hypertension</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CCBs versus ARB for hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with hypertension<br/><b>Settings:</b> outpatients or inpatients<br/><b>Intervention:</b> CCBs versus ARB </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>comments</b> </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>CCBs versus ARB</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause mortality</b><br/>Follow‐up: 2 to 5.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> <br/>(0.92 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25,611<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 3128 (95%CI 143 to 157)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b><br/>(75 to 88) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Myocardial infarction</b><br/>Follow‐up: 2 to 5.5 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.82</b> <br/>(0.72 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25,611<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 157 (95%CI 93 to 492)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b><br/>(26 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Stroke</b><br/>Follow‐up: 2.6 to 5.5 </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.89</b> <br/>(0.76 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>25,611<br/>(6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 226 (95%CI 115 to 8570)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b><br/>(26 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Congestive heart failure</b><br/>Follow‐up: mean 2.6 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.20</b> <br/>(1.06 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>23,265<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 94 (95%CI 59 to 222)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b><br/>(40 to 51) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cardiovascular mortality</b><br/>Follow‐up: mean 2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.79</b> <br/>(0.54 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4642<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>NNT 184 (95% CI 72 to 331)</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b><br/>(13 to 29) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ARB:</b> angiotensin receptor blocker; <b>CCB:</b> calcium channel blocker; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>NNT:</b> number needed to treat </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Only two studies described allocation concealment, and one study had withdrawals.<br/><sup>2</sup>Only three studies described allocation concealment, and one study had withdrawals.<br/><sup>3</sup>I<sup>2</sup> &gt; 60%; direction and size of effect inconsistent.<br/><sup>4</sup>One study of three did not describe allocation concealment, and one study had withdrawals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">CCBs versus ARB for hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/full#CD003654-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003654-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">All‐cause mortality</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 CCBs vs other classes of antihypertensive agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 CCBs vs diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 CCBs vs β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.88, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 CCBs vs diuretics or β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.94, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 CCBs vs ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.91, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 CCBs vs ARBs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">All‐cause mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003654-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Myocardial infarction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 CCBs vs other classes of antihypertensive agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 CCBs vs diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 CCBs vs β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.79, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 CCBs vs diuretics and β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 CCBs vs ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.97, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 CCBs vs ARBs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.72, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Amlodipine vs ACE inhibitors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.91, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Myocardial infarction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003654-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Stroke</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 CCBs vs other classes of antihypertensive agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 CCBs vs diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 CCBs vs β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.67, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 CCBs vs diuretics or β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 CCBs vs ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 CCBs vs ARBs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Amlodipine vs ARBs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003654-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Congestive heart failure</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 CCBs vs other classes of antihypertensive agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 CCBs vs diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.25, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 CCBs vs β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.67, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 CCBs vs diuretics and β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.99, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.4 CCBs vs ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.06, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.5 CCBs vs ARBs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.06, 1.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Congestive heart failure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003654-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Cardiovascular mortality</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 CCBs vs other classes of antihypertensive agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 CCBs vs diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.93, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 CCBs vs β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 CCBs vs diuretics or β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.92, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.4 CCBs vs ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.5 CCBs vs ARBs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.54, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 DHP vs β‐blockers <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.66, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Cardiovascular mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003654-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Major cardiovascular events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 CCBs vs other classes of antihypertensive agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 CCBs vs diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [1.00, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 CCBs vs β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.77, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 CCBs vs diuretics and β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.95, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.4 CCBs vs ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.94, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.5 CCBs vs ARBs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.78, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Sensitivity analysis: CCBs vs ACE inhibitors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.94, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Major cardiovascular events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003654-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Blood pressure reduction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Systolic blood pressure reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 CCBs vs diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.56, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 CCBs vs β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐0.31, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 CCBs vs diuretics or β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [2.59, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.4 CCBs vs ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐1.40, ‐0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.5 CCBs vs ARBs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐2.46, ‐1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.6 CCBs vs α1‐antagonist</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐3.89, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Diastolic blood pressure reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 CCBs vs diuretics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐0.84, ‐0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 CCBs vs β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.16, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.3 CCBs vs diuretics or β‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.07, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.4 CCBs vs ACE inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐0.81, ‐0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.5 CCBs vs ARBs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐1.91, ‐1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.6 CCBs vs α1‐antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐2.39, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Sensitivity analysis: CCBs vs ACE inhibitors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 Systolic blood pressure reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐1.29, ‐0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 Diastolic blood pressure reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐0.81, ‐0.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Blood pressure reduction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003654.pub6/references#CD003654-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003654.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003654-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003654-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003654-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD003654-note-0012">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003654-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003654-note-0015">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD003654-note-0010">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD003654-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD003654-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003654-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003654-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003654\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003654\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003654\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003654\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003654\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003654.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003654.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003654.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003654.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003654.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725885691"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003654.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725885698"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003654.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e862a5ee29371',t:'MTc0MDcyNTg4Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 